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Abstract

TESTING A LOW-INTENSITY AND ACCESSIBLE COGNITIVE BEHAVIORAL
THERAPY FOR INSOMNIA (CBT-I) INTERVENTION IN INDIVIDUALS NEWLY
DIAGNOSED WITH CANCER
By Amma A. Agyemang, M.S., M.P.H.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2015
Major Director: Bruce Rybarczyk
Professor of Psychology
Department of Psychology
Insomnia is defined as difficulty initiating or maintaining sleep, or nonrestorative sleep
that lasts for at least one month and is accompanied by significant impairment in daytime
functioning including fatigue, irritability, and/or difficulty concentrating. It is one of the most
common complaints reported by individuals with cancer, especially around the time of cancer
diagnosis and treatment. Yet it is often unrecognized and untreated, leading to adverse health
consequences and increased healthcare costs. Cognitive Behavioral Therapy for Insomnia (CBTI) has been recommended as the gold standard for treating insomnia among individuals with
cancer. Multiple studies have tested and proven the efficacy and effectiveness of CBT-I among
individuals with cancer. However, only one study has investigated the efficacy of CBT-I in
individuals newly diagnosed with cancer who are undergoing cancer treatment. Moreover,
previous studies have been limited by their focus on largely homogenous samples of White,
well-educated women with breast cancer. The dissemination of CBT-I among individuals with
cancer is greatly limited by the lack of available providers and resources needed to implement
the standard face-to-face treatment. One strategy to address this shortage has been to abbreviate
6

standard CBT-I into low-intensity modalities that require fewer resources and can be selfadministered on the Internet. The current study sought to examine the feasibility and
acceptability, as well as the efficacy of one such program, an online low-intensity CBT-I
intervention, Sleeping Healthy Using the Internet (SHUTi), supplemented with clinician support,
in a sample of individuals newly diagnosed with heterogeneous malignancies who were
undergoing chemotherapy and/or radiation. Results yielded support for the feasibility and
acceptability of addressing individuals’ insomnia with a low-intensity CBT-I intervention while
they are undergoing cancer treatment. With regard to sleep, there were significant treatment
effects observed on a global measure of insomnia severity and on subjective sleep consolidation.
There were also significant treatment effects for depressive symptoms. Findings are discussed in
the context of study limitations and for the purpose of expanding the literature on disseminating
CBT-I early in the cancer care trajectory.

7

Testing a Low-Intensity and Accessible Cognitive Behavioral Therapy for Insomnia (CBT-I)
Intervention in Individuals Newly Diagnosed with Cancer
Insomnia is defined as difficulty initiating or maintaining sleep, or nonrestorative sleep
that lasts for at least one month and is accompanied by significant impairment in daytime
functioning including fatigue, irritability, and/or difficulty concentrating (American Psychiatric
Association, 2000). Insomnia is one of the most common complaints reported by individuals
with cancer. Yet it is often unrecognized and untreated (Graci, 2005; J. Savard & Morin, 2001),
leading to adverse health consequences and increased healthcare costs (Leger & Bayon, 2010; J.
Savard & Morin, 2001; Wade, 2011). Insomnia prevalence ranges from 19% to 30% (Davidson,
MacLean, Brundage, & Schulze, 2002; J. Savard & Morin, 2001), with the highest rates reported
in breast cancer (38%) and lung cancer (37%) (Davidson et al., 2002). These rates are
considerably higher than the prevalence in the general population, which is estimated at 10-15%
(Roth, 2001). Individuals who have cancer and insomnia experience greater depression and
mood disturbances (Bardwell et al., 2008; Donovan & Jacobsen, 2007; J. Savard, S. Simard, S.
Hervouet, et al., 2005; Van Onselen et al., 2010), fatigue (Anderson et al., 2003; Beck, Dudley,
& Barsevick, 2005; Davidson et al., 2002; Donovan & Jacobsen, 2007; Sarna, 1993), decreased
quality of life (Davidson et al., 2002; Redeker, Lev, & Ruggiero, 2000; Vargas et al., 2010), and
likely, increased mortality (J. Savard & Morin, 2001; Theobald, 2004). Thus, examining
insomnia in the context of cancer is critical to improving outcomes for individuals with cancer,
as is evidenced by the wealth of literature examining the co-occurrence of cancer and insomnia
(K. K. Cheng & Lee, 2011; Espie et al., 2008; Fiorentino & Ancoli-Israel, 2006; Graci, 2005;
O'Donnell, 2004; J. Savard, Simard, Blanchet, Ivers, & Morin, 2001).
The accumulated evidence has illuminated important aspects of the nature of insomnia in
cancer. For example, insomnia tends to persist in individuals with cancer, such that as many as

8

75-95% of insomnia cases progress into chronic insomnia (Davidson et al., 2002; J. Savard et al.,
2001), lasting for six months or more. Pain (Grond, Zech, Diefenbach, & Bischoff, 1994),
fatigue (Balachandran, Faiz, Bashoura, & Manzullo, 2013; Roscoe et al., 2007), and mood
symptoms (Van Onselen et al., 2010) have been identified as significant predictors of cancerrelated insomnia. Individuals with clinically significant pain (Sharma et al., 2012) or fatigue
(Davidson et al., 2002) are nearly three times more likely than others to experience sleep
disturbances, whereas those with significant anxiety and depression are nearly five times more
likely to report sleep problems (Sharma et al., 2012). Indeed, cancer-related insomnia rarely
occurs in isolation; more often it presents as part of a symptom constellation consisting of pain,
fatigue, and mood symptoms (Beck et al., 2005; Chen & Tseng, 2006; Donovan & Jacobsen,
2007; Hoffman, Given, von Eye, Gift, & Given, 2007; Sharma et al., 2012). One study found
that as much as 18% of a sample of elderly individuals experienced concurrent insomnia, pain,
and fatigue within weeks of their cancer diagnoses (Kozachik & Bandeen-Roche, 2008). The
evidence further suggests that insomnia underlies important mechanisms in cancer symptom
burden—it mediates the relationships between pain and fatigue (Beck et al., 2005), between
depression and fatigue, and between depression and pain (Stepanski et al., 2009).
When it comes to the timing of insomnia treatment in cancer, the period immediately
after cancer diagnosis and prior to treatment is increasingly being recognized as a critical period.
While for many individuals with cancer, insomnia lingers through cancer survivorship and even
years after cancer treatment (Gooneratne et al., 2007), studies indicate that for most individuals
symptoms peak before and during early treatment (Buick et al., 2000; Phillips, Jim, Donovan,
Pinder-Schenck, & Jacobsen, 2012; Thomas, Bower, Hoyt, & Sepah, 2010; Van Onselen et al.,
2012). Longitudinal studies have found that insomnia is most prevalent (28%) within the first
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two months after diagnosis, when surgery is completed and adjuvant treatment is initiated (J.
Savard, Ivers, Villa, Caplette-Gingras, & Morin, 2011; J. Savard, Villa, Ivers, Simard, & Morin,
2009). Furthermore, individuals with insomnia at the beginning of treatment tend to experience
a chronic course, while those with symptoms that do not reach the threshold for an insomnia
diagnosis (i.e., sleep disturbances without daytime impairment) are much more likely to recover
(J. Savard, Ivers, et al., 2011). Also, the disruption in circadian rhythms that precipitates sleep
disturbances has been found to occur within the first week of a treatment cycle (J. Savard, Liu, et
al., 2009). Taken together, these findings suggest that intervening to improve sleep at the outset
of cancer treatment among those individuals with a comorbid insomnia diagnosis has the
potential to make the greatest impact in terms of benefiting individuals’ coping during treatment.
Despite the clinical significance of insomnia early in the cancer treatment trajectory,
fewer studies have focused on understanding insomnia prior to radiation or chemotherapy
treatment (Ancoli-Israel et al., 2006; Beck et al., 2010; Berger, Farr, Kuhn, Fischer, & Agrawal,
2007; Garrett et al., 2011; Miaskowski et al., 2011; Phillips et al., 2012; Van Onselen et al.,
2010; Vargas et al., 2010). Much more attention has been given to insomnia and sleep
disturbances during and after chemotherapy and/or radiation (Bardwell et al., 2008; Berger,
1997; Berger & Farr, 1999; Berger & Higginbotham, 2000; Carpenter et al., 2004; Costantini,
Ale-Ali, & Helsten, 2011; Davidson et al., 2002; Kuo, Chiu, Liao, & Hwang, 2006; Moore,
Berger, & Dizona, 2011; Payne, Piper, Rabinowitz, & Zimmerman, 2006; Rissling, Liu,
Natarajan, He, & Ancoli-Israel, 2011; J. Savard, Liu, et al., 2009; J. Savard et al., 2001).
Cognitive behavioral therapy for insomnia (CBT-I) is considered gold standard treatment for
comorbid insomnia and its treatment effects are more durable than pharmacological treatments
{Morin, 1999 #123;National Institutes of Health, 2005 #76}. However, there is only one
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published study of CBT-I in individuals prior to chemotherapy initiation (Berger, Kuhn, Farr,
Lynch, et al., 2009). Findings from this study showed that, although a CBT-I plan implemented
before chemotherapy and reinforced during and after chemotherapy resulted in some benefits for
sleep immediately and one year after, it did not confer significant improvements on critical
subjective and objective sleep measures. One study limitation that likely contributed to these
findings is that most participants (60%) reported fairly good or very good sleep at baseline,
leaving little room for improvement. These findings underscore the importance of testing the
efficacy of CBT-I among individuals who are experiencing significant sleep disturbances and
daytime impairment (i.e., meet criteria for insomnia).
Intervening on individuals’ sleep soon after cancer diagnosis and prior to treatment
initiation is not without its challenges. Due to the large number of individuals presenting with
insomnia during a time when engagement in intensive treatment is difficult, the best approach
would likely include a stepped care model that includes low intensity/highly accessible
treatments (self-help and abbreviated) as a first step (Mack & Rybarczyk, 2011). Self-help and
abbreviated treatments have been highly tested in other insomnia groups (Edinger & Sampson,
2003; Rybarczyk, Mack, Harris, & Stepanski, 2011; Wagley, Rybarczyk, Nay, Danish, & Lund,
2012), but to our knowledge, only two self-help treatments have been tested in individuals with
cancer (Ritterband et al., 2012; J. Savard, Villa, Simard, Ivers, & Morin, 2011) and neither study
was conducted with newly diagnosed patients. Previous studies suggest that self-help
approaches are 50-75% as effective as therapist delivered unabridged approaches. The proposed
study will extend previous research (Berger, Kuhn, Farr, Lynch, et al., 2009; Ritterband et al.,
2012) by examining the feasibility and efficacy of a low-intensity and accessible selfadministered CBT-I intervention with clinician support in individuals with cancer. Participants
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will be individuals newly diagnosed with non-advanced (i.e., curable) cancers who have yet to
initiate their first course of chemotherapy or radiation therapy. They must report experiencing at
least three episodes of sleep disturbance per week that is associated with daytime effects such as
fatigue, irritability, or difficulty concentrating and has persisted for at least one month. This
study will seek to address the following two complementary aims: 1) To assess the feasibility
and acceptability of a low-intensity and accessible CBT-I intervention among individuals newly
diagnosed with cancer; and 2) To determine the efficacy of the intervention in improving sleep
and other quality of life outcomes during cancer treatment. In accomplishing these aims, the
proposed study emphasizes increasing implementation and dissemination of CBT-I among
individuals with cancer as suggested in the Reach Effectiveness Adoption Implementation
Maintenance (RE-AIM) model (Glasgow, Vogt, & Boles, 1999), by decreasing barriers related to
time and cost (Glasgow & Emmons, 2007) while seeking to increase feasibility and acceptability
(Klesges, Estabrooks, Dzewaltowski, Bull, & Glasgow, 2005).
Review of the Literature
Insomnia in Cancer
Insomnia is defined as difficulty initiating or maintaining sleep, or nonrestorative sleep,
that lasts for at least one month (American Psychiatric Association, 2000). To meet diagnostic
criteria, the sleep disturbance or associated daytime fatigue must cause clinically significant
distress or impairment. Insomnia that occurs in the context of another medical condition like
cancer is termed Secondary Insomnia or more appropriately, Comorbid Insomnia (American
Psychiatric Association, 2000; National Institutes of Health, 2005). Comorbid insomnia is
functionally equivalent to primary insomnia (Rybarczyk, Lund, Mack, & Stepanski, 2009) and
warrants no less clinical attention. Indeed addressing comorbid insomnia in cancer, which
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affects as many as one-third of all individuals with cancer (Davidson et al., 2002; J. Savard &
Morin, 2001), is especially important because it is more likely to be undertreated due to the
notion among patients and providers that the condition is a less significant (compared to cancer)
and/or is a temporary disturbance for which few effective treatments exist (Fleming & Davidson,
2012). A first step to addressing cancer-related insomnia is to understand its etiology.
Etiological theory of comorbid insomnia in cancer. Much like primary insomnia,
insomnia among individuals with cancer is explained through a diathesis-stress model. This
model posits that a disorder like insomnia results when an environmental stressor triggers an
underlying vulnerability (Morin & Espie, 2003; Spielman, Caruso, & Glovinsky, 1987).
According to Spielman’s 3-P model, insomnia develops when a predisposition or vulnerability to
sleep disturbance (e.g., genetic and personality traits) is triggered by precipitating factors (e.g.,
life stressors, schedule changes), and is maintained when perpetuating factors (e.g., poor sleep
hygiene, maladaptive beliefs about sleep) become entrenched (Spielman et al., 1987). Research
has identified predisposing, precipitating, and perpetuating factors that while not unique to
individuals with cancer, are especially relevant to the development and persistence of insomnia
in this population. Of note, much of the evidence has focused only on precipitating factors.
Predisposing factors. Three of the most relevant predisposing factors for insomnia
among individuals with cancer are psychiatric disorders, older age, and female gender. The cooccurrence of psychiatric disorders like anxiety and depressive disorders with cancer is one
important factor that explains individuals ’ heightened predisposition to insomnia. Since
insomnia or poor sleep is often part of the constellation of anxiety and depressive symptoms, it is
believed that the increased prevalence of these psychiatric disorders in individuals with cancer,
approximated at 49-53%, also increases risk for insomnia (Fleming & Davidson, 2012; J. Savard
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& Morin, 2001). Regarding age, cancer incidence is highest among older individuals (Centers
for Disease Control and Prevention, 2013), making the advanced age of most individuals with
cancer another important predisposing factor (Fleming & Davidson, 2012; J. Savard & Morin,
2001). Finally, being female is a likely relevant predisposing factor for individuals with cancer
(J. Savard, Villa, et al., 2009) given that insomnia is most prevalent in breast cancer (Fleming &
Davidson, 2012). Also, anxiety and depressive disorders are more common in females (Leach,
Christensen, Mackinnon, Windsor, & Butterworth, 2008), thus further increasing the burden of
insomnia for females diagnosed with cancer.
Precipitating factors. Unlike predisposing factors, the factors that precipitate and
perpetuate insomnia are much more amenable to intervention. For individuals with cancer, the
most salient precipitating factor is the experience of being diagnosed with and treated for cancer.
Although insomnia may pre-date cancer diagnosis for some individuals , it is also likely that for
many, the stress and worry that accompany the emergence of cancer-related symptoms, the
process of diagnosis, of surgery and active treatment is enough to trigger the onset of insomnia
(Fleming & Davidson, 2012). Many individuals may respond with fear and distress to their
unusual symptoms prior to diagnosis, which may disrupt their sleep; the extent of the disruption
is likely related to the speed with which they seek medical attention and how quickly a diagnosis
is made once such attention is sought (Fleming & Davidson, 2012).
Findings that insomnia symptoms peak soon after cancer diagnosis and immediately prior
to treatment (Van Onselen et al., 2012) provide clear support for the notion that cancer diagnosis
and treatment precipitate insomnia. Individuals are likely to experience much fear and anxiety
during this period that may disrupt their sleep through various pathways. First, treatment may
aggravate existing pre-treatment symptoms related to the distress of diagnosis (J. Savard, Liu, et

14

al., 2009). Second, surgery, often an initial step of treatment for patients, has been found to more
than double the risk for insomnia in cancer (J. Savard, Villa, et al., 2009). This is partly
attributable to the period of hospitalization associated with surgery as it is associated with
concomitant environmental (e.g., noise, medication-dosing schedules), behavioral (e.g., daytime
napping, modified bedtime routine), and psychological risk factors (e.g., isolation, fear) (Sheely,
1996). Individuals are also likely to experience distress as a result of undergoing an invasive
procedure, which may result in loss in function or an altered appearance (Jacobsen, Roth, &
Holland, 1998). Lastly, active treatment (i.e., chemotherapy, radiation therapy) is associated
with significant physiological changes that can trigger insomnia. For instance, chemotherapy is
thought to disrupt sleep by impairing patients’ rest-activity circadian rhythms as early as after the
first administration (J. Savard, Liu, et al., 2009), leading to decreased differentiation between
daytime and night time activity (Fernandes, Stone, Andrews, Morgan, & Sharma, 2006; Levin et
al., 2005; Parker et al., 2008; Pati et al., 2007), and daily dysfunction (Ancoli-Israel et al., 2006;
Beck et al., 2010). Other biological agents in cancer therapies that contribute to insomnia are
corticosteroids and biological response modifiers. Corticosteroids, like dexamethasone, used to
treat cancer pain and other treatment related side effects, increase cortisol levels, thereby
inducing insomnia (Kirkbride et al., 2000). Similarly, interferon and tumor necrosis factor,
which are used to treat malignant melanoma, can also disrupt patients’ sleep/wake cycles (J.
Savard & Morin, 2001). Besides these biological effects, chemotherapy and radiation treatment
have significant side effects that include pain, fatigue, and emotional distress, which are also
implicated in insomnia. The sheer prevalence of these side effects means that few individuals
with cancer are unaffected; when taken together with the considerable distress they cause, an
examination of how these specific side effects impact insomnia is warranted.
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An estimated 25% of newly diagnosed patients, 33% of those in treatment, and 75% of
those with advanced cancer experience pain (Swarm et al., 2013). Cancer-related pain impairs
patients’ functioning while diminishing their quality of life, and when it is not adequately
controlled early in cancer care, can shorten patients’ survival (Swarm et al., 2013). As might be
expected, cancer pain is one of the most feared symptoms by patients (Swarm et al., 2013).
Insomnia from cancer-related pain can result from the pain in and of itself, or the medications
used to treat the pain (Theobald, 2004). Experimental and clinical studies show that pain
precipitates insomnia by causing micro arousals, thereby lightening sleep and lessening the
restorative benefits of sleep. Individuals with persistent pain may also experience more
nocturnal awakenings due to physiological changes related to pain. Pain can also induce
insomnia by disrupting mood (Smith & Haythornthwaite, 2004).
Approximately 80% of individuals undergoing chemo- and/or radio-therapy report
cancer-related fatigue (Hofman, Ryan, Figueroa-Moseley, Jean-Pierre, & Morrow, 2007). It is
defined as a subjective, persistent, and distressing state of tiredness related to cancer or its
treatment that interferes with usual functioning and is often unrelieved by rest (Berger et al.,
2010). Patients on average consider cancer-related fatigue to be the most distressing symptom of
cancer and its treatment (Berger et al., 2010). Research suggests that cancer-related fatigue is
reciprocally associated with insomnia (Roscoe et al., 2007). Specifically, although fatigue can
result from the physiological effects of cancer or cancer treatment (e.g., anemia) (Anderson et
al., 2003), insomnia also increases daytime fatigue. It is also possible for decreased daytime
activity and restless sleep to exacerbate fatigue, perhaps due to daytime napping and diminished
circadian functioning as a result of inactivity (Berger & Higginbotham, 2000). Subjective and
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objective measures of sleep confirm this complex relationship between insomnia and cancerrelated fatigue.
Lastly, an estimated 50% of individuals with cancer have anxiety and/or depressive
disorders that contribute to and co-vary with sleep disturbances (Phillips et al., 2012; J. Savard &
Morin, 2001; Van Onselen et al., 2012; Woodward, 2011). For example, cancer surgeries that
result in changes in patients’ physical appearance or loss of function may produce greater
emotional distress and thus increase risk for insomnia (J. Savard & Morin, 2001). In some cases,
sleep disturbances can elevate patients’ risk for depression (Fiorentino & Ancoli-Israel, 2014).
Even though emotional distress and insomnia can be related and treating insomnia may improve
emotional adjustment, it is important to note that for many patients, depression and anxiety may
also require attention separate from insomnia treatment (Fiorentino & Ancoli-Israel, 2014).
Perpetuating factors. Chief among the behaviors that maintain insomnia once
precipitated is poor sleep hygiene {Fiorentino, 2006 #17}. Insomnia persists when patients
respond to its onset with maladaptive sleep behaviors that increase arousal and sleep effort,
thereby inhibiting relaxation and sleep. For example, patients may spend more time in bed due
to fatigue when not sleepy, perhaps engaging in activities that interfere with sleep, which
weakens the association between their beds and sleep. Similarly, patients may weaken the
association between sleep and/or relaxation and their bedroom when they repeatedly pair
heightened arousal with their bedrooms by going to their bedrooms when in pain or distress
(Fleming & Davidson, 2012). Also possible, patients may nap during the day in efforts to regain
lost nighttime sleep, or may keep irregular sleep-wake schedules due to the side effects of
treatment. While these behaviors are patients’ attempts to cope with a stressful time period in
their lives and may even be in keeping with treatment recommendations (Woodward, 2011),
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insomnia becomes chronic when these behaviors become habits and persist after acute stressors,
such as treatment, end.
Individuals may also develop faulty beliefs and attitudes about sleep that can perpetuate
insomnia (J. Savard & Morin, 2001; Woodward, 2011). While not unique to individuals with
cancer, one of the most common maladaptive beliefs about sleep that can perpetuate insomnia
includes unrealistic expectations about sleep requirements (e.g., I need 8 hours of sleep each
night). Others are erroneous causal attributions (e.g., If I don’t sleep well, my cancer will come
back); misattribution or exaggeration of the perceived consequences of insomnia (e.g., I’m
always tired because I can’t get a good night’s sleep); and perceived diminished control or
predictability of sleep (e.g., I feel like when and how I sleep is completely out of my control).
These beliefs undermine sleep because they increase anxiety and other negative emotional
responses, thereby increasing arousal at bedtime, which overrides the body’s entrained sleep
response.
Importance of treating insomnia early in cancer care trajectory. The importance of
treating insomnia among individuals with cancer, especially early in the cancer care trajectory
cannot be overstated. Left untreated, the consequences of insomnia for individuals can be
severe. Individuals with concurrent cancer and insomnia experience greater symptom burden
and poorer overall survival (Degner & Sloan, 1995). One study found that insomnia symptoms,
which peaked within the first eight weeks after diagnosis, significantly increased the risk for
death within the first year after cancer diagnosis (Kozachik & Bandeen-Roche, 2008).
According to the current state of the evidence, CBT-I is the treatment of choice for
cancer-related insomnia. However, the efficacy and feasibility of CBT-I during this critical
period of cancer treatment, namely the time surrounding cancer surgery and the initiation of
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active treatment, remains unclear (J. Savard & Savard, 2013). Thus, an important avenue for
research, and the purpose of the current pilot study, is to investigate whether CBT-I can be
implemented as effectively during this time period as observed in other studies, and to examine
whether it will be acceptable to individuals with cancer.
Treatment for Comorbid Insomnia in Cancer
The need for effective insomnia treatment in cancer has led to a proliferation of studies.
First, it must be acknowledged that successful treatment of insomnia in cancer must include
management of cancer-related symptoms such as pain and treatment side effects through
pharmacological and non-pharmacological modalities. As discussed above, these symptoms
contribute to and exacerbate insomnia. However, solely addressing these symptoms is
insufficient, as the behaviors and thought patterns that perpetuate insomnia outlast these
symptoms (J. Savard & Morin, 2001). Moreover, as the National Institutes of Health (NIH)
(2005) State of the Science conference statement asserts, comorbid insomnia is a separate
diagnosis that merits individualized attention. Thus, this review of the evidence on treating
comorbid insomnia in cancer will focus on insomnia-specific treatment.
Pharmacological treatment. As in the general population (Morin & Jarrin, 2013),
hypnotic medications are often prescribed to individuals with cancer who report insomnia.
Recent estimates put hypnotic medication use in this population at 23%, with more than onethird of individuals initiating use at one point or another after their cancer diagnosis (Casault,
Savard, Ivers, Savard, & Simard, 2012). Although hypnotic medications have been shown to be
effective in the short-term in the general population (National Institutes of Health, 2005), they
have yet to be studied in cancer populations (National Cancer Institute, 2013). Additionally,
sleep experts recommend limiting use to two to four weeks (National Institutes of Health, 2005);
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however, patients with cancer were found to be using these medications for an average of five
years (Casault et al., 2012). Not only is evidence for such long-term use lacking (National
Cancer Institute, 2013; J. Savard & Savard, 2013), but long-term use can also have adverse
health consequences, including tolerance, dependence, residual daytime drowsiness, impaired
cognitive functioning, and increased risks for falls and motor vehicle accidents (Glass, Lanctot,
Herrmann, Sproule, & Busto, 2005; J. Savard & Morin, 2001). Among individuals with cancer
specifically, hypnotic medication use is associated with diminished quality of life and increased
symptom burden (Paltiel et al., 2004). Moreover, sustained hypnotic medication use can actually
precipitate insomnia by interfering with rapid eye movement sleep (National Cancer Institute,
2013), as well as perpetuate insomnia because individuals tend to overestimate their efficacy
(Holbrook, Crowther, Lotter, Cheng, & King, 2000). Individuals may also adopt beliefs that
only these medications can treat their insomnia, or that their sleep problems are permanent, due
to their dependence on these medications or the unpleasant withdrawal symptoms they
experience when they attempt to discontinue use. For these reasons, non-pharmacological
treatment, specifically CBT-I, is recommended as first-line treatment for insomnia in individuals
with cancer (National Cancer Institute, 2013).
Cognitive-Behavioral Treatment for Insomnia. CBT-I is a multiple-component
behavioral treatment that aims to decrease the maladaptive behaviors and thought patterns that
perpetuate insomnia (Morin, 2004). It is comprised of stimulus control, sleep restriction, sleep
hygiene, and cognitive restructuring, as well as an optional relaxation training component used
by some clinicians (Smith, Huang, & Manber, 2005).
Stimulus control operates on the notion that after numerous unsuccessful attempts to fall
asleep, individuals with insomnia condition arousal by repeatedly pairing wakefulness with
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bedtime and the sleep setting (Bootzin, 1973). Thus, the stimulus control component of CBT-I
aims to repair the association between sleep and sleep stimuli (i.e.,, bedtime, bed, bedroom), as
well as to restore synchronized circadian rhythms through five specific guidelines: 1) Go to bed
only when sleepy; 2) Use the bedroom only for sleep or sex; 3) Get out of bed whenever unable
to sleep after 15 minutes and only return to bed when sleepy; 4) Wake up at the same time each
morning; and 5) Do not nap during the day (Bootzin, Epstein, & Wood, 1991; Morin, 2004).
Sleep restriction is guided by the principle that insomnia is maintained by the excess
amount of time individuals with insomnia spend in bed not sleeping. Thus, limiting the amount
of time spent in bed creates a temporary state of sleep deprivation or sleep pressure that is
sufficient enough to overpower individuals’ conditioned arousal (Morin, 2004) . The goal of
sleep restriction is to help individuals fall asleep faster, increase sleep continuity and improve
sleep quality and ultimately, to enhance the efficiency of individuals’ sleep. To determine an
individual’s sleep restriction regimen, a “sleep window” (i.e.,, bed- and wake-times) is
established based on the average total sleep time estimated from sleep diaries (Morin, 2004).
Adjustments are made to the “sleep window” over the course of treatment depending on the
patient’s progress and changes in sleep efficiency (Morin, 2004). For example, an individual’s
averaged total sleep time per night is five hours, and she must be up for work at 6 AM.
Therefore, she would be instructed to go to bed no earlier than 1 AM.
Sleep hygiene is the education component of CBT-I that entails teaching individuals
about the external factors that promote and hinder sleep (Morin, 2004). For instance, individuals
are educated about how environmental factors such as light and/or noise in the bedroom can
disrupt sleep. They are counseled to avoid behaviors such as nighttime caffeine, alcohol, or
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nicotine use. Alternatively, they are encouraged to engage in behaviors more conducive to sleep,
including consuming a light snack before bed, and exercising daily.
Cognitive restructuring targets those beliefs, expectations and thought patterns that
interfere with sleep by driving maladaptive behaviors (Morin, 2004). For instance, individuals
may have misconceptions about the causes of insomnia (e.g., “My sleep is poor because I’m
getting old”), have distorted perceptions that amplify the consequences of insomnia (e.g., “If I
don’t get a full night’s sleep, I’ll be sick”), hold unrealistic expectations about sleep (e.g., “I have
to get at least eight hours of sleep at night”), and/or may have dysfunctional beliefs about sleeppromoting practices (e.g., “I should just stay in bed and try harder to sleep”) (J. Savard & Savard,
2013; Woodward, 2011). These beliefs maintain insomnia by heightening individuals’
performance anxiety and by instilling a sense of learned helplessness around sleep, thereby
increasing sleep effort and decreasing the likelihood of sleep (Morin, 2004). In addition to
directly addressing these beliefs by challenging them, cognitive restructuring entails teaching
individuals to: 1) never try to sleep; 2) not catastrophize after a poor night’s sleep; and 3) have
realistic expectations about sleep (Morin, 2004).
Relaxation training can work in concert with the other components of CBT-I to reduce
individuals’ physiologic and cognitive arousal, especially at night, thereby promoting sleep
(Morin, 2004). There are a number of techniques for relaxation training, including progressive
muscle relaxation, an exercise through which individuals are taught to tense and release different
muscle groups to relax their bodies. Another option is guided imagery, in which through mental
representations, individuals are guided to a peaceful scene where they are able to perceive the
experience with their senses (Post-White, 2002).
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Efficacy of CBT-I. The efficacy of CBT-I is well established, with studies yielding large
effect sizes. On average, studies produce a 50-60% reduction in symptoms on key subjective
and objective insomnia outcomes (J. D. Edinger, W. Wohlgemuth, R. Radtke, G. Marsh, & R.
Quillian, 2001a; Espie, Inglis, Tessier, & Harvey, 2001; Morin, Colecchi, et al., 1999; Morin,
Culbert, & Schwartz, 1994; Morin, Hauri, et al., 1999; Smith et al., 2002) among 70-80% of
treated individuals (Woodward, 2011). Treatment gains can last for as long as two years (Morin,
Colecchi, et al., 1999). Specifically, individuals typically report decreases in sleep onset latency
(SOL), the period between laying down to sleep and sleep onset, and wake after sleep onset
(WASO), the amount of time spent awake after sleep onset, to non-clinical levels after treatment
(Edinger et al., 2001a; J. D. Edinger, W. K. Wohlgemuth, R. A. Radtke, G. R. Marsh, & R. E.
Quillian, 2001b; Irwin, Cole, & Nicassio, 2006; Morin, Colecchi, et al., 1999; Morin, Kowatch,
Barry, & Walton, 1993). Improvements in total sleep time (TST) have also been noted, with
individuals reporting average increases of up to 45 minutes (Morin, Colecchi, et al., 1999; Morin
et al., 1993). CBT-I also corresponds with improvements in quality of sleep or sleep
consolidation, as measured by sleep efficiency (Edinger, Hoelscher, Marsh, Lipper, & IonescuPioggia, 1992; Mimeault & Morin, 1999). Finally, individuals who undergo CBT-I report
clinically significant improvements in their self-efficacy to address sleep problems and in their
sleep satisfaction, as well as a decrease in their dysfunctional thoughts and beliefs about sleep
(Edinger et al., 2001a; Edinger et al., 2001b; Morin, Blais, & Savard, 2002; Morin, Colecchi, et
al., 1999).
When compared to pharmacotherapy, CBT-I is a more efficacious and durable treatment
and it has the additional benefit of avoiding the side effects of pharmacological treatments. For
instance, a meta-analysis showed that CBT-I recipients reported significantly greater
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improvements in SOL than those treated with pharmacotherapy, 43% vs. 30% (Smith et al.,
2002). The superior potency of CBT-I over pharmacotherapy is further supported by evidence
that CBT-I alone is equally as, or more efficacious than combining pharmacotherapy with CBT-I
(Jacobs, Pace-Schott, Stickgold, & Otto, 2004). Compared to those receiving pharmacotherapy,
individuals treated with CBT-I are more likely to achieve normal sleep patterns after treatment,
to be satisfied with their sleep, and to perceive their treatment as more effective, (Jacobs et al.,
2004).
Effectiveness of CBT-I. Although requisite, establishing treatment efficacy is
insufficient evidence for the feasibility or generalizability of CBT-I to real world settings. This
is especially important given that in real world settings, individuals with insomnia also present
with comorbid psychiatric and medical conditions (Morin, Stone, McDonald, & Jones, 1994).
Compared to efficacy studies, the literature on the clinical effectiveness of CBT-I is less
developed. Early evidence of the effectiveness of CBT-I came from case series studies of
treatment-seeking patients from sleep clinics (Dashevsky & Kramer, 1998; Morin, Stone, et al.,
1994; M Perlis et al., 2000; M Perlis, Sharpe, Smith, Greenblatt, & Giles, 2001), and also from
primary care clinics (Espie, Inglis, Tessier, et al., 2001; Espie, Inglis, & Harvey, 2001; Espie,
MacMahon, & Kelly, 2007). Nevertheless, the evidence is unequivocal that the efficacy of CBTI is generalizable to more heterogeneous patient populations, including those with comorbid
medical and psychiatric conditions (Smith et al., 2005). In particular, CBT-I was associated with
26-65% improvement in SOL, 48-50% improvement in WASO, 13-28% improvement in TST,
and 14-33% improvement in SE (Okajima, Komada, & Inoue, 2011). Moreover CBT-I
recipients reported decreases in hypnotic medication use (Espie, Inglis, Tessier, et al., 2001;
Morgan, Dixon, Mathers, Thompson, & Tomeny, 2003; Morin et al., 2004; Morin, Colecchi,
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Ling, & Sood, 1995) and on multiple quality of life indicators (Dixon, Morgan, Mathers,
Thompson, & Tomeny, 2006; Morgan et al., 2003).
CBT-I Format. Despite its proven efficacy and effectiveness, CBT-I remains underused
as a result of low availability and accessibility due to a lack of resources including limited
availability of trained clinicians (Edinger & Means, 2005). This has prompted research into
understanding the optimal dosing for treatment effect as well as the efficacy and effectiveness of
abbreviated CBT-I, and into less resource-intensive treatment modalities. This line of research
also extends the evidence on the effectiveness of CBT-I, as it tends to use more heterogeneous
samples, with a goal of increasing dissemination of CBT-I.
Low-intensity CBT-I. Edinger et al. (2007) provided the basis for this line of
scholarship, by demonstrating that contrary to expectations, one- and four-session CBT-I
treatment outperformed the two- and eight-session treatments. Other studies have demonstrated
that abbreviated CBT-I, constituting two to three sessions (face-to-face and over the telephone),
is effective in significantly improving sleep among primary care patients (Buysse et al., 2011;
Edinger & Sampson, 2003), psychiatric outpatients (Wagley et al., 2012), and among older
adults with medical and psychiatric comorbidities (Germain et al., 2006). Overall, low-intensity
CBT-I, including self-administered interventions, have been shown to be 50-75% as clinically
effective as face-to-face unabridged treatments (Rybarczyk, Lopez, Schelble, & Stepanski, 2005;
Rybarczyk et al., 2011).
Self-administered CBT-I. In addition to abbreviating sessions, research suggests that
dissemination of CBT-I can be greatly expanded through self-administered modalities like
Internet-based computerized programs. In fact, a recent meta-analysis found six different
randomized controlled trials (RCTs) of computerized CBT-I, comprising 433 study participants
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(S. K. Cheng & Dizon, 2012). Findings showed up to moderate effect sized improvements in the
following outcomes: number of awakenings, WASO, TST, SOL, time in bed (TIB), SE, and
sleep quality. There were also large improvements in subjective insomnia symptoms and
consequences. Moreover, adherence among participants in computerized CBT-I was 78%,
higher than the rates reported in face-to-face CBT-I (S. K. Cheng & Dizon, 2012).
Self-administered CBT-I with clinician support. Although comparable to standard CBTI, self-administered CBT-I results in smaller treatment effects (J. Savard, Ivers, Savard, & Morin,
2013; van Straten & Cuijpers, 2009) that are clinically significant (Currie, Clark, Hodgins, &
El‐Guebaly, 2004). Augmenting self-administered interventions with clinician support is one
strategy to address this limitation. Adding clinician support to self-administered CBT-I increases
the intensity of the treatment, but it remains on the continuum of a low-intensity treatment.
Several studies support that supplementing self-help CBT-I with clinician support enhances
treatment effects (Ho, Chung, Yeung, Ng, & Cheng, 2014; Jernelöv et al., 2012; Kaldo et al.,
2015). Most recently Kaldo and colleagues (2015) found that when compared to an active
control treatment that entailed sleep hygiene, relaxation, mindfulness and general stress
management, guided CBT-I resulted in clinically meaningful improvements in insomnia
symptoms that was sustained 12 months post treatment.
Taken together, the evidence clearly supports abbreviated and computerized CBT-I as
viable strategies for disseminating this efficacious and effective treatment. First, these treatment
modalities help meet the varying needs of individuals with insomnia, as not all may require the
full, intensive, treatment protocols. Secondly, they address the time- and resource-demands that
make face-to-face CBT-I unfeasible in certain clinical settings or among certain patientpopulations. Individuals with cancer who are about to initiate active cancer treatment fall into
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this latter category. Given that cancer treatment is such a taxing time, individuals may find lowintensity CBT-I more acceptable. This line of research inquiry is supported by a small, but
promising body of literature on the efficacy and effectiveness of CBT-I among individuals with
cancer.
CBT-I in cancer. To date, there have been 15 published studies on the efficacy of CBTI among individuals diagnosed with cancer (Berger, Kuhn, Farr, Lynch, et al., 2009; Davidson,
Waisberg, Brundage, & MacLean, 2001; Epstein & Dirksen, 2007; Espie et al., 2008; Fiorentino
& Ancoli-Israel, 2006; Garland et al., 2014; Matthews, Schmiege, Cook, Berger, & Aloia, 2012;
Quesnel, Savard, Simard, Ivers, & Morin, 2003; Ritterband et al., 2012; J. Savard, Simard, Ivers,
& Morin, 2005; J. Savard, Villa, et al., 2011; Simeit, Deck, & Conta-Marx, 2004). The strongest
support for CBT-I among individuals with cancer is provided by RCTs. Nine of the published
studies have been RCTs, with individual (Berger, Kuhn, Farr, Lynch, et al., 2009; Fiorentino &
Ancoli-Israel, 2006; Matthews et al., 2012; J. Savard et al., 2013), group (Epstein & Dirksen,
2007; Espie et al., 2008; Garland et al., 2014; J. Savard, S. Simard, H. Ivers, et al., 2005), or
computerized designs (Ritterband et al., 2012). Treatments have typically entailed four to eight
15- to 120-minute in-person sessions. These studies have proven the efficacy of CBT-I at
improving sleep among individuals with cancer on key sleep parameters including SOL, WASO,
and SE, and self-rated insomnia, as well as at conferring benefits in psychological well-being and
quality of life. When tested, these therapeutic gains can be maintained for up to 12 months after
treatment.
These studies are not without their limitations. First, the samples in these RCTs have
been especially homogenous, as all or the majority of participants have been diagnosed with
breast cancer. Second, all, but one of these studies, have been conducted among individuals who
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are months or years post-diagnosis and -treatment. For example, in the first RCT published,
Savard and colleagues (2005) randomized 57 breast cancer survivors who were on average 31
months post treatment, to an eight-session group CBT-I protocol or to a wait-list control. The
CBT-I protocol was standard, including stimulus control, sleep restriction, sleep hygiene, and
cognitive restructuring. Findings showed that compared to the control group, CBT-I recipients
showed significantly greater improvement on subjective and some objective measures of sleep,
with treatment gains maintained and even enhanced for some participants at the twelve-month
follow-up. Additionally, CBT-I was associated with significant decreases in depression and
anxiety, and increase in global quality of life. More recently, Fiorentino et al. (2009) reported
similar results in a crossover design study of breast cancer survivors five to 24 months post
treatment. After completing the six-session individual standard CBT-I protocol plus progressive
muscle relaxation, 71% of participants experienced a remission in their sleep disturbances.
There were significant improvements on subjective (i.e.,, WASO, SE) and objective (i.e.,,
actigraph-measured WASO, sleep percentage) sleep measures.
Berger et al. (2009) completed the only RCT to date in individuals with cancer who were
also undergoing chemotherapy. In the study, 219 individuals with breast cancer were randomly
assigned to CBT-I or a healthy eating control treatment condition. Prior to chemotherapy,
individuals in the CBT-I condition developed an Individualized Sleep Promotion Plan with a
nurse, covering modified stimulus control and sleep restriction, sleep hygiene, and relaxation.
The sleep plan was revised prior to each subsequent cycle of treatment, with reinforcements
scheduled seven days after each revision. Post-CBT-I, individuals reported significantly fewer
awakenings and higher sleep efficiency, as well as fewer actigraph-measured awakenings.
Findings from this study support the feasibility and efficacy of implementing CBT-I prior to and
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during active cancer treatment. Nevertheless, this examination of the benefits of CBT-I during
this critical point of the cancer treatment trajectory was likely limited by the exclusion of
individuals with chronic insomnia, leaving a largely non-clinical insomnia sample, a majority of
whom self-identified as “fairly good” or “very good” sleepers.
Low-intensity CBT-I in cancer. Given its demonstrated efficacy, researchers in recent
years have sought to increase the dissemination of CBT-I among individuals with cancer through
self-help versions of CBT-I. Pioneering this kind of work, Savard et al. (2011) examined the
feasibility of a self-help CBT-I intervention composed of a 60-minute video and a 20-page
booklet on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring. In the
single-group study design, participants were recruited during radiotherapy and were given the
intervention materials after completing a two-week sleep diary. Participants were instructed to
read a segment of their intervention booklet and to watch a segment of the video each week, for
six weeks. There were significant, large effect-sized improvements in perceived sleep quality,
SOL, WASO, and SE, moderate effect-sized improvements in depression and quality of life, as
well as small effect-sized decrease in use of sleep medications, with many of these treatment
gains generally maintained at the three-month follow-up. Moreover, these findings are
especially promising in light of results that the self-reported adherence was 100%, while the
attrition rate (18%) is comparable to that reported in a clinician-led intervention trial (16-18%)
(Espie et al., 2008). However, the true efficacy of this self-help CBT-I has yet to be tested, as
there was no control group to rule out the effects of time and/or treatment expectancies.
In the second self-help CBT-I study, Ritterband and colleagues (2012) evaluated the
efficacy of Sleep Healthy Using The Internet (SHUTi), an individually-tailored, interactive
Internet-based CBT-I treatment protocol, among cancer survivors who were on average, 48
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months post-treatment. Of note, unlike previous studies, only individuals who self-reported that
their cancer diagnosis or treatment precipitated or exacerbated their sleep problems were eligible
to participate. The SHUTi program consists of six 45 to 60-minute cores covering stimulus
control, sleep restriction, sleep hygiene, and cognitive restructuring. Participants are provided
with individualized tailoring and feedback throughout the program based on sleep diary data that
they enter. Additionally, automated emails are sent to participants to inform them of next steps
and to encourage adherence. Post-intervention, the authors found that compared to the waitlist
control group, SHUTi completers reported statistically significant and clinically meaningful
improvements in multiple sleep outcomes. In particular, SHUTi produced 19% improvement in
SE, 59% improvement in SOL, and large effect-sized improvement in self-rated sleep quality.
Lastly, treatment effects for fatigue, ranging from moderate to large, was observed in the SHUTi
group. Similar to the other self-help CBT-I study reviewed (J. Savard, Villa, et al., 2011),
adherence was high, with 86% of participants completing the SHUTi program, which is
comparable to adherence reported in a clinician-led intervention (Berger et al., 2003).
Both of these studies of self-help CBT-I had limitations that were similar to previous
RCTs. In both studies participants were individuals with breast cancer who were months or
years post-treatment. In fact, in one study, active cancer treatment was considered an exclusion
criterion (J. Savard, S. Simard, H. Ivers, et al., 2005). As in other CBT-I studies among
individuals with cancer, the study samples have lacked racial and ethnic diversity, as the majority
have been well-educated Caucasian women. Despite these shortcomings, these studies have
provided very favorable results about the efficacy and feasibility of implementing low-intensity
CBT-I interventions among individuals with cancer. In addition to producing treatment effects
on key insomnia outcomes comparable to those in face-to-face interventions, findings suggest
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that these interventions can also produce clinically meaningful benefits on other psychosocial
outcomes including fatigue and quality of life. These studies add to the growing knowledge base
on effective strategies for translating and disseminating CBT-I among individuals with cancer.
Self-administered CBT-I with clinician support in cancer. There has been only one study
that has tested the efficacy of a self-administered CBT-I supplemented with clinician support in
individuals diagnosed with cancer. Building on previous work, Savard and colleagues (2013)
compared the efficacy of a low-intensity CBT-I intervention, a video-based intervention with six
booklets, supplemented with clinician support to a standard, face-to-face intervention in women
who had undergone treatment for breast cancer. The authors found that the low-intensity
intervention resulted in clinically significant improvements on several sleep parameters. These
treatment effects were smaller than those found for the face-to-face intervention (J. Savard et al.,
2013). Moreover, even though clinician support was offered, 9% of participants in the lowintensity treatment condition accessed this support.
Among the strongest arguments for these low-intensity CBT-I programs for patients,
especially those already burdened with cancer, are their flexibility and convenience, which may
enhance their acceptance and adherence. Preliminary data seem to support this, as the reported
adherence rates have been higher than those reported in a face-to-face group CBT-I study. One
research question that remains unanswered is the feasibility and efficacy of these low-intensity
CBT-I interventions during the early stages of active cancer treatments, when patients are most
likely to experience insomnia.
Considerations. In pursuit of the study aims, there were a number of considerations
related to cancer and to Internet usage. The literature clearly supports treating individuals with
cancer who also have comorbid insomnia with CBT-I, but there were a number of considerations
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unique to the experiences of this population. The first has to do with the fatigue (Smith et al.,
2005) and pain (National Cancer Institute, 2013) associated with cancer and its treatment. As
described earlier, pain and fatigue can precipitate insomnia, as well as contribute to maladaptive
thinking patterns and behaviors that perpetuate sleep disturbances. Thus, any CBT-I regimen for
individuals with cancer, particularly if implemented during active cancer treatment, must address
how these side effects impact sleep. For some patients, these cancer treatment side effects may
require separate pharmacologic and non-pharmacologic management. For example, tricyclic
antidepressants can be especially beneficial for treating sleep disturbances in patients with
neuropathic pain and depression (National Cancer Institute, 2013). Additionally, nonpharmacologic strategies can be embedded in CBT-I treatment components. For instance,
stimulus control and sleep hygiene can correct some individuals’ tendency to respond to cancerrelated pain and fatigue by spending additional time in bed by setting activity/exercise goals, and
timing naps appropriately to limit their interference with nighttime sleep (National Cancer
Institute, 2013; Smith et al., 2005). To reinforce those instructions, cognitive restructuring can
also be used to adjust patients’ misattributions of fatigue with sleep loss, while helping
individuals distinguish between fatigue (i.e., decreased energy, such as a sense of heaviness in
limbs, which may require rest but not necessarily sleep) and sleepiness (i.e., requiring effort to
stay awake) (Smith et al., 2005). Also, relaxation techniques can be implemented in conjunction
with pain management and to reduce conditioned arousal at bedtime.
Other considerations were related to cancer-specific psychological distress and age.
Given the high co-occurrence of psychological distress, including depression and anxiety, with
cancer and insomnia, these symptoms must also be appropriately managed in order to achieve
the full benefit of CBT-I. Psychiatric symptoms were assessed to determine whether they
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required separate psychotherapy or pharmacologic intervention (Smith et al., 2005). Lastly,
older individuals with cancer and comorbid insomnia may have required important modifications
to CBT-I protocols (National Cancer Institute, 2013). For instance, sleep hygiene and cognitive
restructuring could be tailored to address the changes in sleep cycles that occur as part of the
natural aging process. Thus, older patients were engaged in cognitive restructuring to develop
more realistic expectations of their sleep.
Lastly, since that the current study examined the feasibility and efficacy of an online
program, considerations regarding Internet access must be discussed. To accurately capture
patients’ CBT-I treatment preferences rather than their Internet access, prospective participants
needed regular access to the Internet. Based on current evidence on Internet access, the potential
for this requirement to have biased study findings was limited. An estimated 85% of American
adults use the Internet (Pew Internet and American Life Project, 2011), with 72% of users having
searched for health-related information (Fox & Duggan, 2013). Moreover, differences in access
by socioeconomic status (SES) have decreased significantly (U.S. Government of Commerce,
2000) and access is similar across different racial and ethnic minority groups—86% of nonHispanic Whites compared to 85% of non-Hispanic Blacks and 76% of Hispanic adults reported
using the Internet in 2013 (Pew Internet and American Life Project, 2011). Given the increased
rates of cancer among older adults, it is also important to note that Internet access is increasing in
this segment of the population, with 83% of adults aged 50-64, and 56% of adults aged 65 and
older using the Internet (Pew Internet and American Life Project, 2011; Zickuhr & Madden,
2012). These statistics further supported the importance of examining the acceptability and
efficacy of an online CBT-I intervention, given that access to face-to-face CBT-I is limited.
Statement of the Problem
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CBT-I is an evidence-based, efficacious and effective treatment for cancer-related
insomnia. The treatment improves sleep, psychological and physical symptoms, with treatment
gains that last for up to 12 months. With the utility of CBT-I in cancer firmly established,
research efforts have recently turned to accelerating the translation and dissemination of CBT-I
to a greater number of patients through low-intensity treatment modalities. To date, only two
studies of a web-based and a video plus treatment booklet self-help interventions have been
tested. One study added clinician support to the self-administered treatment. Overall, these
studies have yielded very promising findings, demonstrating that CBT-I, even in its low-intensity
forms, can have clinically meaningful and lasting effects on sleep, depression, quality of life, and
fatigue. Moreover, participants appear to respond well to these treatments, with adherence rates
higher than those reported in face-to-face studies, and comparable attrition rates. However, these
findings are limited by the homogenous, non-representative nature of the study samples, when it
comes to demographic characteristics and malignancy type. Second, despite evidence supporting
the importance of treating CBT-I in the early phases of cancer treatment, only one CBT-I study
and none of the low-intensity CBT-I studies, has been conducted during active cancer treatment.
This study aimed to address these gaps in the literature while extending previous research
on accelerating the translation and dissemination of CBT-I among individuals with cancer
through low-intensity treatment modalities. This study examined the feasibility, acceptability,
and efficacy of a low-intensity and accessible CBT-I intervention delivered online, SHUTi, with
therapist support provided as needed. Participants were individuals newly diagnosed with nonadvanced (i.e.,, curable) cancers who were about to initiate their first course of chemotherapy or
radiation therapy, and were experiencing at least three episodes of sleep disturbance per week
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that was associated with daytime effects such as fatigue, irritability, or difficulty concentrating
and had persisted for at least one month. The following complementary aims were examined:
Specific Aim 1: To assess the feasibility and acceptability of an online CBT-I
intervention, Sleeping Healthy Using the Internet (SHUTi), in individuals newly
diagnosed with cancer.
Specific Aim 2: To determine the efficacy of SHUTi at improving sleep and other
quality of life outcomes during cancer treatment.
Statement of Hypotheses
Based on past evidence and the aims of the current study, the following hypotheses were
proposed:
1. SHUTi will be a feasible and acceptable treatment for insomnia among patients newly
diagnosed with cancer who are undergoing chemotherapy and/or radiation.
2. Compared to the treatment as usual (TAU) group, participants in the SHUTi group
will report significantly better sleep after treatment, as indicated by lower Insomnia
Severity Index (ISI) score, higher SE, decreased SOL, higher TST, and shorter
WASO.
3. Compared to the TAU group, participants in the SHUTi group will report
significantly better health-related quality of life and lower psychological distress (i.e.,
depression and anxiety) after treatment.
Methods
Study Design
The current study examined the feasibility and efficacy of a low-intensity and accessible
CBT-I intervention delivered online, SHUTi, among patients newly diagnosed with cancer who
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were treatment naïve and undergoing chemotherapy and/or radiation at an academic medical
center. Participants were randomized to either the SHUTi condition or TAU group. All
participants had a face-to-face meeting with the doctoral student at enrollment, when baseline
self-report questionnaires were completed (see Measures section for further detail). As a pretreatment assessment, all participants also completed a 1-week sleep diary. Participants
randomized to SHUTi were enrolled in the program and provided with their login information at
the end of the pre-assessment period. SHUTi participants were informed that they had the option
of accessing the doctoral student’s assistance to complete the program at any time during the
study period. Specifically, she would be available to meet them at their weekly appointments to
provide a tablet for them to complete the program cores either with her or independently during
their appointments. Individuals randomized to TAU were contacted by telephone biweekly or in
person if the doctoral student saw them during an appointment while she was meeting with
another study participant. These phone calls and in-person visits mimicked the level of contact in
the treatment condition to encourage participant engagement. However, during these contacts,
no advice regarding sleep was given and if participants asked for help, they were encouraged to
discuss their concerns with their oncologists. Individuals in the TAU group were also given the
option of receiving SHUTi if interested at the end of the study period. However, none of the
patients in the TAU condition chose to complete SHUTi. At the end of the study period, all
participants completed a 1-week diary and the same standardized questionnaires completed at
baseline. Participants in the SHUTi condition also completed a questionnaire about the
acceptability of the program.
Participants
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Twenty-eight adults (i.e., 18 years and older) diagnosed with non-advanced (i.e., curable)
cancer who were about to initiate chemotherapy and/or radiation treatment for the first time
participated in this study. None of the participants had widely disseminated (i.e., metastatic)
disease at the time of recruitment. These individuals were eligible if they reported experiencing
at least three episodes of sleep disturbance per week that was associated with daytime effects
such as fatigue, irritability, or difficulty concentrating and had persisted for at least one month.
Participants were recruited from the Virginia Commonwealth University (VCU) Massey
Cancer Center. The VCU Massey Cancer Center is an NCI-designated cancer center that
provides comprehensive cancer care through multidisciplinary teams. These teams convene at
weekly tumor board meetings to discuss patients and to design treatment plans. There are tumor
board meetings for specific cancer sites: head and neck, ear, nose and throat; breast; chest;
gastrointestinal; gynecological; and prostate and other urologic. In addition to these
multidisciplinary teams, there is also a Fellows clinic, in which hematological/oncology medical
fellows see patients, who are primarily indigent or uninsured, with various malignances. Prior to
their initial treatment appointments with their oncologist, potential participants were identified
through case presentations at these tumor board meetings and at the Fellow’s clinic, chart review,
and oncologist referral.
Inclusion criteria were as follows: a) newly diagnosed non-advanced (i.e., curable)
cancer; b) scheduled or planned to begin chemotherapy or radiotherapy; c) chemotherapy- or
radiotherapy-naïve; c) meet diagnostic criteria for chronic insomnia (i.e., lasting for at least one
month); d) interested in contributing to the understanding of insomnia in cancer; and e) have the
permission of their oncologists to participate. Chronic insomnia has been defined in previous
research (Edinger et al., 2004; Rybarczyk, Stepanski, et al., 2005) as the presence of (1) three or
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more episodes of insomnia (i.e.,, ≥ 30-minute SOL, ≥ 60-minute WASO, or ≤ 6.5 hour-TST per
night) of per week and (2) daytime effects of insomnia, such as irritability, difficulty
concentrating, or fatigue for at least one month. Exclusion criteria were: a) untreated alcohol or
substance abuse or dependence, bipolar, or psychotic disorder; b) medical conditions such as
seizure disorder, restless leg disorder, or Parkinson’s disease; and c) untreated sleep disorders
such as sleep apnea. Other CBT-I efficacy and effectiveness trials have used these exclusion
criteria (Smith et al., 2005) because sleep restriction may be riskier in bipolar or seizure disorder
as it may precipitate a manic episode or lower the seizure threshold. Similarly, Parkinson’s
disease may cause sleep disturbances (Rybarczyk, Stepanski, et al., 2005).
The sociodemographic characteristics for the analytic sample (N=28) and for participants in the
SHUTi (n=14) and TAU (n=14) conditions are presented in Table 1. F-tests (for continuous
variables) and chi-square analyses (for categorical variables) were used to verify the success of
randomization by examining whether there were any significant differences by condition at
baseline. No significant differences were found between the SHUTi group and the TAU group
with regard to gender, age, race, marital status, education, employment, income, and insurance
status (all p values > .05).

Table 1. Sociodemographic characteristics of sample at baseline
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Characteristic
Gender, n (%)
Females
Males
Age, M (SD)
Range
Race, n (%)
White
Black
Asian
Marital status, n (%)
Married
Single
Divorced/Separated/Widowed
Education, n (%)
Some High School
High School
Some College
College
Graduate School
Employment, n (%)
Full time
Part time
Unemployed
Disability
Income, n (%)
<$10, 000
$10-29, 999
$30-49, 999
$50-74, 999
$75-99, 999
$100, 000
Insurance, n (%)
Indigent/uninsured
Medicaid/VCC
Medicare
Private

Overall (N=28) CBT-I (n=14)

TAU (n=14)

22 (78.6)
6 (21.4)
47 (10.8)
23-63

11 (78.6)
3 (21.4)
43 (10.2)
37-49

11 (78.6)
3 (21.4)
50 (10.4)
44-56

18 (64.3)
9 (32.1)
1 (3.6)

9 (64.3)
4 (28.6)
1 (7.1)

9(64.3)
5 (35.7)
0

13 (46.4)
7 (25.0)
8 (28.6)

6 (42.9)
5 (35.7)
3 (21.4)

7 (50.0)
2 (14.3)
5 (35.7)

1 (3.6)
6 (21.4)
12 (42.9)
5 (17.9)
4 (14.3)

0
3 (21.4)
5 (35.7)
3 (21.4)
3 (21.4)

1 (7.1)
3 (21.4)
7 (50.0)
2 (14.3)
1 (7.1)

10 (35.7)
9 (32.1)
5 (17.9)
4 (14.3)

5 (35.7)
5 (35.7)
2 (14.3)
2 (14.3)

5 (35.7)
4 (28.6)
3 (21.4)
2 (14.3)

8 (28.6)
7 (25.0)
2 (7.1)
2 (7.1)
2 (7.1)
7 (25.0)

4 (28.6)
3 (21.4)
2 (14.3)
1 (7.1)
1 (7.1)
3 (21.4)

4 (28.6)
4 (28.6)
0
1 (7.1)
1 (7.1)
4 (28.6)

5 (17.9)
5 (17.9)
1 (3.6)
17 (60.7)

3 (21.4)
1 (7.1)
0
10 (71.4)

2 (14.3)
4 (28.6)
1 (7.1)
7 (50.0)

Baseline insomnia- and cancer-related characteristics for the total sample and by group
are presented in Table 2. F-tests and chi-square analyses found no significant differences
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between the SHUTi group and the TAU group with regard to these characteristics including
cancer site, stage, time since cancer diagnosis, and type of cancer treatment (all p values > .05).
Baseline descriptive statistics of the outcome variables (ISI, SOL, WASO, SE, FACT-G
and its component scores, PHQ-9 and GAD-7) for the sample and by group at baseline are
presented in Table 3. F-tests and chi-square analyses were performed to examine whether there
were any significant differences in outcomes of interest by group. Since these tests are sensitive
to violations of normality, variables found to be high on skewness and/or kurtosis were adjusted.
Adjustments were performed by converting data points with z-scores greater than 1.96 (p < .05)
to the next closest value that was under the cut-off value from the sample for that variable. This
method maintains the shape of the sample distribution without distorting the data (Tabachnick &
Fidel, 2007) and was determined to be the most appropriate way of addressing outliers given the
small sample size (Taylor, Rybarczyk, Nay, & Leszczyszyn, 2015). Results showed that the two
groups were equivalent with regard to all outcome variables (all p values > .05).
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Table 2. Cancer- and insomnia-related characteristics at baseline
Characteristic
Overall (N=28) CBT-I (n=14)
Cancer site, n (%)
Breast
10 (35.7)
3 (21.4)
Gastrointestinal
7 (25.0)
5 (35.7)
Head & neck
6 (21.4)
4 (28.6)
Gynecological
4 (14.3)
1 (7.1)
Other
1 (3.6)
1 (7.1)
Stage at diagnosis, n (%)
I
6 (21.4)
4 (28.6)
II
6 (21.4)
1 (7.1)
III
9 (32.1)
6 (42.9)
IV
5 (17.9)
2 (14.3)
Other
2 (7.1)
1 (7.1)
Months since diagnosis, M (SD) 2 (1.8)
1.5 (0.85)
Surgery
18 (64.3)
8 (57.1)
Type of treatment, n (%)
Chemotherapy
14 (50.0)
8 (57.1)
Radiation
3 (10.7)
0 (0)
Chemo-radiation
11 (39.3)
6 (42.9)
Duration of insomnia, n (%)
≤ 5 months
14 (51.9)
10 (71.4)
6-12 months
3 (11.1)
1 (7.1)
1-5 years
1 (3.7)
1 (7.1)
≥ 6 years
10 (33.3)
2 (4.3)
Onset of insomnia, n (%)
Before cancer diagnosis
21 (75.0)
9 (64.3)
After cancer diagnosis
7 (25.0)
5 (35.7)
Cancer caused insomnia, n (%) 11 (39.3)
8 (57.1)
Cancer affected sleep, n (%)
24 (85.7)
13 (92.9)
Told oncologist about sleep
11 (39.3)
8 (57.1)
problems, n (%)
Use of sleep aid, n (%)
15 (55.6)
8 (57.1)
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TAU (n=14)
7 (50.0)
2 (14.3)
2 (14.3)
3 (21.4)
0
2 (14.3)
5 (35.7)
3 (21.4)
3 (21.4)
1 (7.1)
2.4 (2.3)
10 (71.4)
6 (42.9)
3 (21.4)
5 (35.7)
4 (31.8)
2 (15.4)
0
7 (53.8)
12 (85.7)
2 (14.3)
3 (21.4)
11 (78.6)
3 (21.4)
7 (53.8)

Table 3. Descriptive statistics of the outcome variables at baseline
Overall
CBT-I
Characteristic
(N=28)
(n=14)
Insomnia Severity Index (ISI), M (SD)
13.6 (6.2) 13.7 (4.7)
Sleep Onset Latency in minutes (SOL), M (SD) 63.9
50.3 (33.5)
(58.9)
Wake Time After Sleep Onset in minutes
44.8
51.8 (40)
(WASO), M (SD)
(35.1)
Sleep Efficiency % (SE), M (SD)
69.6
72.8 (15.8)
(17.3)
Total Sleep Time in minutes, M (SD)
372.2
419.8
(130.6)
(143.9)
Functional Assessment of Cancer Therapy72.2
67.4 (15.6)
General (FACT-G), M (SD)
(16.1)
Physical Well-being Score
19.2 (5.9) 17.8 (6.3)
Emotional Well-being Score
15.8 (4.4) 15.3 (4.1)
Social/Family Well-being Score
22.6 (6.2) 21.3 (7.8)
Functional Well-being Score
14.7 (6.9) 12.9 (6.2)
Patient Health Questionaire-9 (PHQ-9), M
10.2 (4.4) 10.6 (4)
(SD)
Generalized Anxiety Disorder-7 (GAD-7), M
8.8 (5.1)
8.5 (3.9)
(SD)

TAU
(n=14)
13.4 (7.6)
77.5 (75.5)
37.8 (29.2)
66.4 (18.9)
324.6 (99)
77.5 (15.6)
20.6 (5.1)
24 (3.5)
24 (3.5)
16.4 (7.3)
9.8 (5.3)
9 (6.3)

Procedure
The study protocol was approved by Massey Cancer Center’s Protocol Review and
Monitoring Committee (PRMC), MCC-14-1076, and the VCU Institutional Review Board
(IRB), HM20002827.
Recruitment. Study participants were recruited between December 2014 and August
2015. Before recruitment for the study could begin, the doctoral student presented the study and
eligibility criteria to the multidisciplinary teams at tumor board meetings and at the
hematology/oncology Fellows’ pre-clinic conferences. The doctoral student then attended these
weekly tumor board meetings to identify potential study participants from the list of new patients
that were discussed at each meeting. Other potential participants were identified at the
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hematology/oncology Fellows’ pre-clinic conferences, where patients who would be seen in the
clinic that same day were discussed. Potential participants’ ability to participate in the study was
verified with their oncologists at the tumor board meetings and at the pre-clinic conferences. In
addition to these active recruitment strategies, there was passive recruitment through fliers that
were placed in areas of prominence at Massey.
The doctoral student approached patients during a pre-treatment appointment using a
standardized verbal introduction to describe the study while also informing patients that their
oncologists had given prior approval for their participation. This introduction took place either
before or after patients had met with their oncologists. While these visits were usually one of the
first times individuals were meeting with their oncologists, individuals were only approached
after they had discussed their treatment plans with their oncologist. Interested individuals were
formally assessed for other eligibility criteria, particularly, that they met diagnostic criteria for
insomnia. Participants that met eligibility criteria and expressed interest in participating in the
study were then consented into the study. The doctoral student reviewed consent forms with
eligible individuals to ensure that they understood the study procedure and their rights as
participants. After which, participants were asked to give written informed consent. After
consent, enrolled participants were administered baseline assessments. In a few cases, potential
participants were identified after they had already had a pre-treatment visit and did not have any
upcoming appointments scheduled before their first treatment appointment. In those cases,
individuals were approached about the study over the telephone and eligible individuals were
also consented over the telephone, though written consent was obtained at the first meeting with
the doctoral student. Baseline questionnaires were also completed over the telephone and these
individuals were emailed their baseline sleep diaries so that they would have them completed
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before they met up with the doctoral student at their first treatment appointment. Once consented,
each patient was enrolled into either the SHUTi or TAU arm by random assignment.
Randomization. The randomization process was as follows. Prior to beginning the
study, a random number generator (www.randomization.com) was used to produce a random
permutation of integers from 1 to 30. This list was then matched with a systematic listing of 30
total treatment and control condition assignments (e.g., T, C, T, C, etc.) For example, if the
random number generator produces 1, 23, 15, and 27, these numbers will determine the first four
group assignments, so that first patient will be assigned to the treatment condition (T), the 23rd to
the control condition (C), 15th to the treatment condition (T), and the 27th to the control condition
(C). Thus at enrollment, the patient’s assignment to the treatment or control condition was
already determined.
At least one week after study enrollment, the doctoral student met with each study
participant, whether in the SHUTi or TAU condition to collect baseline sleep diary data. This
visit took place either before or at the first chemotherapy or radiation treatment appointment. At
this meeting, individuals in the SHUTi condition were enrolled in the program and given their
login information. Whenever possible, an introductory module that teaches users about the
program and its features was also completed at this visit, to facilitate participants starting on the
actual treatment portion of the program as immediately as possible. At this time, individuals
were also asked about their preference for completing the treatment either independently or with
the doctoral student’s assistance. For participants who chose to work with the doctoral student,
arrangements were made to meet at subsequent treatment appointments. For participants who
chose to complete the program independently, the doctoral student monitored their progress with
completing SHUTi Cores online and individuals were contacted either over the telephone or in
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person if they failed to log onto the program for more than 1-2 weeks. Additionally, the option
of completing the program at their treatment appointments with or without the doctoral student’s
assistance was presented again. In contrast, individuals in the TAU condition were told that they
would be contacted biweekly, either on the telephone or in person, until the end of the study
period once they completed the baseline sleep diary.
At the end of the study period, all participants completed the same questionnaires that
they completed at baseline. Participants in the SHUTi condition also completed a questionnaire
on the acceptability of the program. Questionnaires were completed either in person or over the
telephone depending on the participants’ availability. Participants were also asked to complete a
1-week sleep diary, which was either collected at a subsequent appointment or emailed to the
doctoral student.
Compensation. To incentivize participation, individuals enrolled in the study were
given two $10 Visa gift cards. At enrollment, participants were informed verbally and through
the written study consent form that they would be provided a small compensation for their
participation. Participants who completed baseline questionnaires and returned a completed
baseline 1-week sleep diary were given the first $10 gift card. Participants received the second
$10 gift card after they completed post-treatment period questionnaires and returned a completed
post-treatment 1-week sleep diary.
SHUTi. An overview of the SHUTi intervention is presented in Figure 3. The online
program is made-up of six, weekly treatment Cores modeled after weekly face-to-face CBT-I
sessions (Thorndike et al., 2008). Each Core began by providing a rationale for learning the
material, explained the main content of the Core, and assigned homework with suggestions for
improving sleep over the coming week. Each Core ended with a summary review of the main
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points in the Core. The main content for each Core addressed myths about sleep, discussed indepth information and vignettes, and used quizzes to evaluate users’ learning in an interactive
manner. As well as being interactive, SHUTi allowed for personalization. For instance,
modifications were made to sleep recommendations based on participants’ sleep diary data and
individually set treatment goals.
The first Core of SHUTi is the Overview, which provided a review and rationale of
insomnia and its treatment, including the impact of insomnia, its risk factors, and the
effectiveness of CBT-I. Second is the Sleep Behavior Core, which introduced and implemented
sleep restriction as well as stimulus control. The next Core is Sleep Behavior Core 2 and built on
the previous Core by addressing concerns about sleep restriction while expanding on stimulus
control instructions. The fourth Core is the Sleep Education Core, which focused on teaching
sleep hygiene, particularly the lifestyle and environmental factors that influence sleep. The fifth
Core is the Sleep Thoughts Core, aptly named for its focus on cognitive restructuring.
Last is the Problem Prevention Core, which sought to synthesize information from the previous
five cores to solidify users’ knowledge and to prevent future problems by preparing users to cope
with eventual increase in insomnia symptoms.
Each Core took approximately 45 to 60 minutes to complete. Cores were presented one
at a time; the next Core became available to users a week after they completed one Core.
However, users were able to revisit previous Cores as often as possible. Similar to an in-person
CBT-I intervention, users were not required to keep sleep diaries after the baseline 1-week diary
that was used to establish an initial sleep window. However, they were able to continue
completing sleep diaries if they choose to, and the program used a built-in algorithm to make
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necessary adjustments to users’ sleep diaries if they continued to enter sleep diary data during the
treatment.
Measures
All study measures were self-reported due to the unfeasibility and cost concerns of
objective measures like polysomnography and actigraphy. The use of only self-report measures
is not uncommon in insomnia studies like this (Smith et al., 2005). All study measures are
included in the Appendix.
Study eligibility questionnaire. Individuals who expressed interest in the study after
being approached by the doctoral student were administered a brief questionnaire to assess their
eligibility. To be eligible, individuals had to have been diagnosed with non-advanced cancer and
scheduled to undergo curative chemotherapy and/or radiation (i.e., not palliative). They also had
to be chemotherapy and radiation naïve. This was verified via chart review. Regarding sleep,
individuals had to report experiencing difficulty initiating (i.e., inability to fall asleep within 30
minutes) or maintaining sleep (i.e., awakening during the night for a total of 60 minutes), early
morning awakenings (i.e., achieving less than 6.5 hours of sleep) at least three days a week.
These sleep difficulties had to be associated with daytime consequences such as fatigue,
irritability, or difficulty concentrating. All of these symptoms had to have persisted for at least
one month. Thus, individuals had to answer “Yes” to all questions on the questionnaire to be
eligible for participation. They also had to answer “No” to the exclusion criteria. Specifically,
individuals were ineligible to participate if they reported untreated sleep apnea, seizure disorder,
substance/alcohol use disorder, psychotic disorder, restless leg syndrome, or Parkinson’s disease.
Participant information/Demographic questionnaire. The doctoral student
administered a paper and pencil questionnaire to assess the history and current nature of
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individuals’ insomnia and cancer. In particular, the questionnaire asked about the time of cancer
diagnosis and when treatment would/had begun. Participants were also asked about the duration
of their sleep disturbance. The questionnaire also asked individuals about their perception of the
relationship between their sleep difficulties and their cancer diagnosis. In particular, they were
asked whether they believed their sleep difficulties pre-dated or developed subsequent to their
cancer diagnosis. They were also asked whether they had talked to their oncologist about their
sleep difficulties, and if they were taking a sleep aid. The questionnaire also collected
participants’ demographic information including age, education, income, and employment status.
Sleep diary. Standardized sleep diaries from SHUTi were used to measure and track key
sleep quality indicators (Thorndike et al., 2008). Sleep diaries consisted of twelve questions
including questions about the length of naps, use of sleep aids, bedtime, minutes to fall asleep,
number and duration of nighttime awakenings, wake time, time of getting out of bed.
Individuals were also asked about alcohol use and its timing. Lastly, participants were able to
write in any comments about their sleep they found pertinent. Data from the sleep diaries were
used to calculate SOL, WASO, TST, and SE.
Insomnia Severity Index (ISI). The ISI is an empirically valid seven-item global
measure of perceived sleep difficulties (Bastien, Vallieres, & Morin, 2001) that has been also
been validated in individuals with cancer (M. Savard, Savard, Simard, & Ivers, 2005).
Respondents were asked to rate the perceived severity of their current sleep problems,
satisfaction with their sleep, perceived sleep-related impairment, how noticeable they believe
that impairment is to others, and the amount of distress associated with the sleep disturbance.
All ratings were reported on a 0 to 5 scale, for a 0-28 total score, with higher scores indicating
greater insomnia severity. The ISI has been evaluated as a reliable and validated measure of
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insomnia that is sensitive to treatment response in clinical populations, including individuals
with cancer (Bastien et al., 2001; M. Savard et al., 2005).
Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a self-report version of the
depression module from the PRIME-MD, a diagnostic measure for common psychiatric
disorders (Kroenke, Spitzer, & Williams, 2001). It is a 9-item instrument used to measure
depressive symptoms and functional impairment that is used to diagnose Major Depressive
Disorder and to track treatment progress. Items correspond to DSM-IV-TR diagnostic criteria
(American Psychiatric Association, 2000). The PHQ-9 has been found to be a valid and reliable
measure and has diagnostic validity comparable to the original clinician administered instrument
(Kroenke et al., 2001) and has been widely used to screen for depression among cancer
individuals (Strong et al., 2008; Walker et al., 2011).
Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is a brief, 7-item self-report
screening measure of generalized anxiety symptoms (Spitzer, Kroenke, Williams, & Lowe,
2006). The measure was developed from the DSM-IV-TR diagnostic criteria for Generalized
Anxiety Disorder (American Psychiatric Association, 2000). The measure has been empirically
validated (Lowe et al., 2008) and has been found to be an appropriate measure of anxiety
symptoms among individuals with cancer (L. F. Brown, Kroenke, Theobald, Wu, & Tu, 2010;
Kroenke et al., 2009).
Functional Assessment of Cancer Therapy-General scale (FACT-G). The FACT-G
is a valid and reliable measure for evaluating general quality of life among individuals with
cancer undergoing cancer treatment (Cella et al., 1993). Items assess individuals’ symptoms and
ability to perform activities in the following domains: Physical well-being, social/family wellbeing, emotional well-being, and functional well-being. The instrument has been used as an
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outcome measure in numerous intervention studies among individuals with cancer (Rogers et al.,
2009; Segal et al., 2009; Velikova et al., 2004).
Treatment acceptability questionnaire. To evaluate the acceptability of SHUTi among
participants, a 12-item questionnaire was adapted from questionnaires used by Thorndike and
colleagues (2008) for the initial evaluation of the utility and impact of SHUTi. Participants were
asked to rate their perception of the suitability, ease of use, and effectiveness of SHUTi on a 5point Likert scale where 1 corresponded “Not at All” and 5 corresponded with “Very.” Sample
questions were, “How effective do you think this program will be as a long term cure?” and
“How acceptable do you think the program would be for patients like you?” Participants were
also asked to provide comments about their experiences with SHUTi.
Data Analysis
Statistical analyses were performed using IBM SPSS Statistics - Version 23 and
G*Power – Version 3.1.9.2. Only the twenty-eight participants that completed all baseline
measures were included in the analyses. Additionally, a “last observation carried forward"
method was used to address instances of missing data. For two participants who completed the
TAU period but failed to complete the post-treatment questionnaires and sleep diaries, their
baseline data was used in place of post-treatment data. This is a conservative approach to
addressing missing data due to attrition when analyzing treatment effects. The method limits
attrition bias while strengthening any conclusions that can be made about the intervention
(Kazdin, 2003). To verify results, a sensitivity analysis was also performed wherein the analyses
were repeated with missing data and results were similar to results when the “last observation
carried forward” was used.
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To standardize effects for ease of interpretation, Cohen's d was reported as a measure of
effect size. As a general rule, the cutoff is d = 0.20 for a small effect size, d = 0.50 for a medium
effect size, and d = 0.80 for a large effect size (Cohen, 1988). Cohen’s d was calculated using
G*Power – Version 3.1.9.2. (Faul, Erdfelder, Lang, & Buchner, 2007).
Outline of Analyses by Hypotheses
Hypothesis 1. To test the first hypothesis that online CBT-I (i.e., SHUTi) would be a
feasible and acceptable treatment for insomnia in individuals newly diagnosed with cancer who
are undergoing chemotherapy and/or radiation, a number of indicators were examined. These
indicators were: (1) Recruitment; (2) completion rate; (3) time to complete study and reasons for
delays; (4) use and impact of doctoral student support; (5) SHUTi acceptability among
participants; and (6) participants’ comments about their experiences using SHUTi.
Hypothesis 2. To test the second hypothesis that compared to the group, participants in
the SHUTi group would report significantly better sleep after treatment, repeated measures
multivariate analysis of variance (MANOVA) was used. The independent variable (IV) was
condition (SHUTi vs. TAU) and the repeated factor was time (baseline and post-treatment). The
dependent variables (DVs) were the five indices of sleep quality—total score on the ISI, and the
four sleep parameters calculated from sleep diary data, SOL, TST, WASO and SE. Follow-up
repeated measures analyses of variance (ANOVAs) were also conducted to assess condition by
time interactions for individual sleep variables.
Hypothesis 3. To test the third hypothesis that compared to the TAU group, participants
in the SHUTi group would report significantly better health-related quality of life and lower
psychological distress after treatment, repeated measures MANOVA was used. The IV was
condition (SHUTi vs. TAU) and the repeated factor was time (baseline and post-treatment). The
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DVs were total scores on the PHQ-9, GAD-7, and on the FACT-G and its individual
components. Follow-up repeated measures ANOVAs were also conducted to assess condition by
time interactions for individual outcome variables.
Results
Hypothesis 1: Study Acceptability and Feasibility
Recruitment. The recruitment and retention of study participants is illustrated in Figure
1. Study recruitment took place from December 2014 to August 2015. A total of 53 individuals
were approached or responded to recruitment fliers posted for the study. Out of these
individuals, 83% were screened for study eligibility. The reasons why patients refused to be
screened for the study are presented in Table 4. Among the total number of patients who were
screened, 68% were found to meet inclusion criteria. Most of the excluded patients (57%) were
not experiencing sleep problems and if they were, they were not distressed by the symptoms and
thus did not meet diagnostic criteria for insomnia. Only 14% of the excluded patients were
excluded due to not having Internet or an email account. Although there was a study tablet
available that patients could have used, they further explained that they were not comfortable
using the Internet. Once screened and found to be eligible, 100% of these patients agreed to
participate in the study and were consented.
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Figure 1. Recruitment and Retention of Study Participants
49 patients from VCU Massey Cancer Center (VCU MCC) newly
diagnosed with cancer and about to begin chemotherapy and/or
radiation identified at tumor board meetings and Fellows’ clinic
were approached and introduced to the study by the graduate
student after obtaining permission from their oncologists.
4 patients contacted the graduate student about participation in the
study after seeing fliers posted around VCU MCC.

44 patients were screened for enrollment in the study.

31 patients who met inclusion criteria were enrolled and randomized
to CBT-I or TAU.

1 participant
did not return
baseline sleep
diary and did
not respond to
attempts to
contact.
1 participant
asked to drop
out of the study
due to feeling
overwhelmed.

16 Randomized to
CBT-I

15 Randomized to
TAU

16 participants
completed baseline
measures

14 participants
completed baseline
measures

14 completed pretreatment sleep diary

14 completed pretreatment sleep diary

14 participants were enrolled in
SHUTi
• 11 patients completed all 6 cores
• 3 patients completed ≤30% of cores

14 participants completed posttreatment measures including
post-treatment sleep diary

• 7 patients were
uninterested.
• 2 patients
declined due to
distress.
• 1 patient
deemed
inappropriate
by oncologist.
13 patients were
found to be
ineligible
• 7 patients were
good
sleepers/not
distressed by
sleep problems.
• 4 had already
completed/starte
d treatment.
• 2 patients did not
have
Internet/email
1 participant did
not complete
baseline measures
and did not
respond to
attempts to
contact.

14 participants
completed TAU period

12 participants completed posttreatment measures including
post-treatment sleep diary
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1 participant
died.
1 participant
did not
respond to
attempts to
contact.

Table 4. Reasons for Deciding not to Participate in Study (n=10)
Reason
Not interested in study
Feeling stressed about upcoming cancer treatment
Oncologist deemed patient to be inappropriate

Number of Patients
7
2
1

Completion rate. Overall, 84% of the total number of participants that were randomized
completed the study and all post-treatment questionnaires. This corresponds to a 13% attrition
rate for the SHUTi group (n=3) and a 20% (n=3) attrition rate for the TAU group. In the SHUTi
group, one participant completed the baseline questionnaires but failed to complete the baseline
sleep diary and was subsequently lost to follow-up. Even though this patient was enrolled in
SHUTi, only the training module was completed. Another participant randomized to SHUTi
asked to drop out of the study before being enrolled in the program. Among the participants who
were enrolled in SHUTi, 79% (n=11) completed all the six Cores. The rest of the participants
completed at least 30% or two of the Cores. Reasons participants gave for not completing the
program are enumerated in Table 5. In the TAU group, one patient never completed the baseline
questionnaires or the sleep diary and was lost to follow-up. Among the participants who
completed the TAU period, one participant died and thus post-treatment data was not collected.
Another participant was lost to follow-up.

Table 5. Reasons for not Completing SHUTi (n=3)
Reason
Program does not work well on cell phone
Sleep improved after initial increase in symptoms at diagnosis
and beginning of treatment
Experienced treatment complications and found it difficult to
continue program
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Number of Patients
1
1
1

Time to complete study and delays. The study period was initially planned to last nine
to ten weeks for each participant. There would be a one-week pre-treatment period when
patients would complete their baseline sleep diaries. The treatment period would last
approximately six to seven weeks and then the post-treatment sleep diaries would be completed
during week 9 or week 10. Instead, the study period lasted approximately four months on
average and lasted as long as six months for some patients. However, the study period was
equivalent between the SHUTi and TAU groups. Data collection was completed in December
2015.
There were a number of reasons for these delays. First, some participants experienced
delays with beginning treatment. Approximately 13% of the study participants experienced
treatment delays that lasted from one to several weeks. Immediately prior to beginning
treatment, two participants’ most recent scans showed disease progression and their disease had
to be upstaged. Thus, adjustments had to be made to these participants’ treatment plans. In
another patient, treatment was delayed to allow for additional time for healing from neo-adjuvant
surgery. In the last participant, treatment was delayed due to the participant becoming sick and
requiring time for recovery.
Once treatment was initiated, there were additional delays due to side effects, infections,
and participants’ competing demands. Once participants began chemotherapy and/or radiation
treatment, 37% of participants experienced some form of delay during the study period. For two
of the participants, the onset of the side effects was within the first two treatments, and required
hospitalization and for one of the participants, the hospitalization was for several weeks. In one
participant, the severity of side effects was such that chemotherapy was discontinued
prematurely; though the patient went on to receive radiation. This participant required additional
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time to recover before resuming SHUTi. Another participant experienced further disruption in
sleep due to high dosages of pain medications and decided to resume SHUTi after completing
the part of the treatment regimen when pain medications were needed, so that a more regular
sleep schedule could be maintained. One participant continued to work during treatment,
making completing SHUTi less of a priority and contributing to delays with completing the
program. Another participant, who was undergoing oral chemotherapy, was unresponsive to
attempts to contact for approximately 1 month. Thus, the doctoral student was only able to reach
the participant during a medical appointment.
Finally, collecting post-treatment was delayed by additional instances of hospitalizations
and disease progression. One participant was hospitalized due to treatment-related complications
and disease progression. For another participant, scans showed disease progression, which
necessitated multiple appointments with different providers before it was eventually determined
that palliative treatment and hospice care would be most appropriate. Another participant had a
young child and other work responsibilities that contributed to some delay with completing posttreatment measures and the post-treatment sleep diary.
Doctoral student support and impact for SHUTi. Approximately 91% of the SHUTi
participants who completed all six Cores did so with the assistance of the doctoral student.
Among these participants, 60% initially accepted the doctoral student’s assistance. She met with
them during at least six treatment or other medical appointments and provided a tablet for them
to complete the Cores. The level of assistance varied by participant. Some participants required
as little assistance as setting up the Core and answering questions, whereas for one participant,
the doctoral student completed each Core with the participant. The remaining 40% of the
participants initially opted to complete the Cores independently. However, they experienced
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significant delay with completing the program. Three of the participants experienced delay due
to disease-related complications and the other patient experienced an increase in distress such
that attempts to contact were unsuccessful and the doctoral student had to wait for a medical
appointment for face-to-face contact. Thus these participants were only able to complete the
program with the doctoral student calling them weekly and working with them to complete the
Cores over the telephone.
Thus, with regard to doctoral student support, participants who completed SHUTi can be
classified into four different categories: (1) No support (9%); (2) Initially accepted moderate
support (45%); (3) Initially accepted full support (9%); and (4) Initially refused but accepted full
support due to unexpected delays (36%). These groups of participants differed in
sociodemographic characteristics and in the time required for SHUTi completion. Participants
who initially accepted the doctoral student’s (moderate or full) support completed the program
within ten weeks, while participants who initially chose to work independently took
approximately four months to complete the program. As far as sociodemographic differences,
approximately 67% of the participants who initially opted to complete the program with the
doctoral student’s assistance were African American. In other words, all African American
participants in the SHUTi group initially opted to complete the program with the doctoral
student’s assistance. Participants who initially worked with the doctoral student also were more
likely to be unemployed (33%) or on disability (33%). In comparison, participants who initially
opted to work independently were more likely to have part-time (67%) or full-time (33%)
employment.
SHUTi acceptability. Participants’ ratings for the acceptability and utility of SHUTi are
presented in Figure 2. Overall, SHUTi participants rated the program as being moderately
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acceptable, with an average acceptability rating of 3.6 (1-5 scale). The highest rated items had to
do with the program’s ease of use (4.1) and comprehensibility (4.8). Participants rated the
program acceptability for themselves and for others like them in the moderate range, 3.9 and 3.6
respectively. In contrast, the item that was given the lowest rating (2.9) was the item that asked
about the program’s suitability for helping with early morning awakenings. Similarly, items
regarding the program’s utility for addressing difficulty initiating (3.0) and maintaining sleep
(3.1) received lower ratings. On average, participants reported moderate adherence to the
program’s recommendations (3.2).

Figure 2. Acceptance of SHUTi among Participants (n=14)
1.00

2.00

3.00

4.00

How easy was the web program to use?

5.00
4.14

How convenient was the web program to use?

3.86

How easy was the information to understand?

4.79

How much did you like the web program?

3.57

How consistent was the program with information
from your doctors?

3.46

How acceptable was the web program for you?
How acceptable do you think the program would
be for patients like you?
How suitable did you find the program for
helping you get to sleep?
How suitable did you find the program for helping
you stay asleep?
How suitable did you find the program for helping
you with waking up too early?
How effective do you think this pgoram will be as
a long-term cure?
How able were you to follow through with the
program's recommendations?
Overall
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3.93
3.64
3.00
3.07
2.86
3.29
3.21
3.59

SHUTi participants’ comments. Participants randomized to SHUTi provided
comments on their experiences with the program. Among the favorable comments, one
participant cited the sleep hygiene component as being particularly helpful, “The part I found
most helpful about the program was the setup for my bedroom to make my room more
comfortable and relaxing for good sleep.” Another participant reported that completing the sleep
diaries had been beneficial for correcting misperceptions about the amount of sleep, “I found it
most helpful to realize how much I was actually sleeping because it was more than I thought.”
Two participants mentioned that the doctoral student had been a positive aspect of the program,
with one reporting, “I don’t know how acceptable or effective the program would have been
without the counselor.”
Participants also offered comments unique to the context of individuals with new cancer
diagnoses navigating active treatment. One participant spoke about the fit of the program for
patients, “I think it’s a great program for people with insomnia. I don’t think it was very helpful
for people with illness.” Another participant expressed concerns about the timing of the
program, “I think within a month of diagnosis, it’s natural to not be sleeping, it’s a matter of
time. I think it would be better if we were asked questions about sleep rather than a program.
The program made it more a problem; it was more stress than needed. It would have been better
once things had settled, after a treatment plan was set.” Lastly, one participant spoke about the
difficulty of completing the program while experiencing treatment side effects, “The program
wasn’t convenient to use because I wasn’t feeling good. I didn’t like that I had to access a
computer because it wasn’t great on my phone. I would have liked it better on paper or in
person. I’m lazy, I like medications.”
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The remainder of participants’ comments pertained to difficulties related to SHUTispecific features. Three participants mentioned that it was difficult to try to complete the
program on their cell phones, which made it inconvenient. One participated stated, “I didn’t find
completing the diaries intuitive, there was no default after completing a diary, so I had to change
it every time I logged in. And it didn’t work well on my cell phone.”
Hypothesis 2: Change in Sleep Variables by Group.
A repeated measures MANOVA was performed to examine the second hypothesis that
SHUTi would improve participants’ sleep at post-treatment when compared to the TAU
condition. Due to the assumptions underlying repeated measures MANOVA (Mayers, 2013), the
data was first checked for any violations, including normality and multicollinearity. Initially,
several variables were highly skewed and/or kurtotic (values outside the range of -1.5 to 1.5).
Transforming several outliers addressed this violation. To identify outliers, standardized zscores for baseline and post-treatment values of the outcome variables were calculated. This
method entailed identifying values that corresponded to z-scores greater than 1.96 (p < 0.05) and
converting them to the next closest value below the cut-off value (i.e., the value that corresponds
to the highest non-significant z-score) for that variable. This method is appropriate for
addressing outliers in small samples because it does not distort the data in order to maintain the
sample distribution (Tabachnick & Fidel, 2007) and the method has been used previously in
similar studies (Taylor et al., 2015). In all, ten total data points were converted. Baseline data
points that were converted were ISI (Z = 2.14); SOL (Z = 3.02, Z = 2.43); TST (Z = 2.08); and
WASO (Z = 3.23). Post-treatment data points that were converted were SOL (Z = 4.76); TST (Z
= 2.26); and WASO (Z = 3.51, Z = 2.29, Z = 2.03).
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Next, multicollinearity among the outcome variables was examined by running bivariate
Pearson correlations. Results showed that SE was highly correlated (r > ± 0.7, p < 0.05) with
several other variables and Box’s M Test of Equality could not be calculated due to this
violation. Thus, SE was removed from the MANOVA and examined independently. When
Box’s M Test of Equality was calculated again without SE in the model, the assumption was
found to be satisfied. To test the assumption of equality of error variances, Levene’s Test of
Equality of Error Variances values for the variables were examined. Results showed that with
the exception of SOL, all values were nonsignificant (p > 0.05). However, because the sample
sizes are equivalent between groups, the effects of this violation are mitigated. Nevertheless,
Pillai's Trace will be the test statistic reported because it is robust to violations of the assumption
of homogeneity of variance/covariance matrices when there are two equivalent groups (Field,
2009).
Results of the MANOVA model using TST, ISI, WASO, and SOL as dependent
variables showed a significant time by group interaction, Pillai’s Trace = 0.337, F(4, 23) = 2.92,
p < 0.05. Follow-up repeated measures ANOVAs found a significant time by group interaction
for ISI, Pillai’s Trace = 0.262, F(1, 26) = 9.25, p < .05; and for WASO, Pillai’s Trace = 0.195, F
(1, 26) = 6.31, p < .05. See Figures 3 and 4. There were no significant time by group
interactions for TST (p = 0.323) or SOL (p = 0.908). See Figures 5 and 6.
Before running the repeated measures ANOVA for SE, the assumption of sphericity or
homogeneity of the variances between groups was verified by calculating Mulchy’s Test of
Sphericity. Results showed that all Epsilons were equal to 1, indicating that the assumption was
met. When SE was examined independently in a repeated measures ANOVA, there was a trend
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toward a significant time by group interaction, Pillai’s Trace = 0.118, F(1, 26) = 3.47, p = 0.074.
See Figure 7.

Figure 3. Change in Insomnia Severity Index (ISI) Scores from Baseline to Post-Treatment in
SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Figure 4. Change in Wake Time After Sleep Onset (WASO) in Minutes from Baseline to PostTreatment in SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Figure 5. Change in Total Sleep Time (TST) in Minutes from Baseline to Post-Treatment in
SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Figure 6. Change in Sleep Onset Latency (SOL) in Minutes from Baseline to Post-Treatment in
SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Figure 7. Change in Sleep Efficiency (SE), % from Baseline to Post-Treatment in SHUTi and
Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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With regard to effect sizes calculated with Cohen’s d, there was a medium effect size
observed for ISI (Cohen’s d = 0.60) and for WASO (Cohen’s d = 0.49). There were small effect
sizes observed for SE (Cohen’s d = 0.37), and TST (Cohen’s d = 0.20). See Table 6.

Table 6. Means (Standard Deviation) and Effect Sizes of Sleep-Related Variables in CBT-I and
TAU Groups at Baseline and Post-Treatment
Post-Treatment
Effect
Baseline M (SD)
M (SD)
Size
(d)
CBT-I TAU
CBT-I
TAU
14.0
13.4
6.3 (5.0) 12.8
0.60
Insomnia Severity Index (ISI)*
(4.80)
(7.63)
(4.7)
50.3
77.5
36.0
65.1
0.03
Sleep Onset Latency (SOL)
(33.5)
(75.5)
(31.03)
(67.8)
Wake Time After Sleep Onset
51.8
37.8
23.3
40.4
0.49
(WASO)*
(39.9)
(29.2)
(28.4)
(4.0)
419.8
324.6
482.4
342.7
0.20
Total Sleep Time (TST)
(143.9)
(99.0)
(123.0)
(102.1)
72.8
66.4
85.1
66.8
0.37
Sleep Efficiency (SE)
(15.8)
(18.9)
(12.1)
(21.9)
*p<0.05
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Hypothesis 3: Change in Depression, Anxiety, and Health-related Quality of Life.
A repeated measures MANOVA was performed to examine the third hypothesis that
SHUTi would decrease participants’ depression and anxiety while increasing their health-related
quality of life at post-treatment when compared to the TAU condition. Due to the assumptions
underlying repeated measures MANOVA (Mayers, 2013), the data was first checked for any
violations, including normality and multicollinearity. Initially, several variables were highly
skewed and/or kurtotic (values outside the range of -1.5 to 1.5). Transforming outliers addressed
this violation. To identify outliers, standardized z-scores for baseline and post-treatment values
of the outcome variables were calculated. This method entailed identifying values that
corresponded to z-scores greater than 1.96 (p < 0.05) and converting them to the next closest
value below the cut-off value (i.e., the value that corresponds to the highest non-significant zscore) for that variable. This method is appropriate for addressing outliers in small samples
because it does not distort the data in order to maintain the sample distribution (Tabachnick &
Fidel, 2007) and the method has been used previously in similar studies (Taylor et al., 2015). In
all, five total data points were converted. Baseline data points that were converted were PHQ-9
(Z = 2.33) and GAD-7 (Z = 2.40). Post-treatment data points that were converted were PHQ-9
(Z = 2.52) and GAD-7 (Z = 2.33, Z = 2.14).
Next, multicollinearity among the outcome variables was examined by running bivariate
Pearson correlations. Results showed that FACT-G was highly correlated (r > -0.7, p < 0.05)
with PHQ-9 and GAD-7 scores. Thus, FACT-G was removed from the MANOVA and
examined independently. To test the assumption, the correlation between the dependent
variables is equal between the groups, Box’s M Test of Equality was examined. Results from the
test were not significant (p > 0.05), indicating that the assumption is satisfied. To test the
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assumption of equality of error variances between the groups, Levene’s Test of Equality of Error
Variances values for the variables were examined. Results showed that none of the values were
significant (p > 0.05). Thus this assumption was also satisfied. Nevertheless, Pillai's Trace will
be the test statistic reported due to its robustness and for uniformity across analyses.
Depression and anxiety. Results of the MANOVA model using PHQ-9 and GAD-7 as
dependent variables did not show a significant time by group interaction. However, there was a
trend toward significance, Pillai’s Trace = 0.180, F(2, 25) = 2.74, p = 0.084. Follow-up repeated
measures ANOVAs found a significant time by group interaction for PHQ-9, Pillai’s Trace =
0.159, F(1, 26) = 4.93, p < 0.05. There was no significant time by group interaction for GAD-7
(p = 0.587). See Figures 8 and 9. With regard to effect size, there was a small effect size
observed for PHQ-9 (Cohen’s d = 0.43). See Table 7.

Figure 8. Change in Patient Health Questionnaire-9 (PHQ-9) from Baseline to Post-Treatment in
SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Figure 9. Change in Generalized Anxiety Disorder-7 (GAD-7) Scores from Baseline to PostTreatment in SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers Adjusted)
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Table 7. Means (Standard Deviation) and Effect Sizes of Depression, Anxiety, and HealthRelated Quality of Life in CBT-I and TAU Groups at Baseline and Post-Treatment
Baseline M (SD)
Post-Treatment
Effect
M (SD)
Size
CBT-I
TAU
CBT-I TAU
(d)
Patient Health Questionnaire-9*
10.9 (4.1) 9.8 (5.3) 6.9 (4.5) 9.1 (5.0) 0.43
Generalized Anxiety Disorder-7
8.7 (4.0)
9.0 (6.3) 6.5 (5.3) 5.9 (5.2) 0.11
(GAD-7)
Functional Assessment of Cancer 67.5
77.5
76.4
78.7
0.23
Therapy-General (FACT-G)
(16.1)
(15.6)
(20.0)
(17.7)
17.8 (6.3) 20.6
18.5
18.9
0.18
Physical Well-being
(5.1)
(6.5)
(5.6)
15.3 (4.1) 15.3
19.1
17.5
0.31
Emotional Well-being
(4.1)
(4.7)
(5.1)
21.3 (7.8) 23.9
22.3
25.5
0.03
Social/Family Well-being
(3.5)
(7.4)
(10.2)
16.5 (7.3) 12.9
16.8
15.8
0.22
Functional Well-being
(6.2)
(7.9)
(7.2)
*p<0.05
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Health-related quality of life. Results from Mulchy’s Test of Sphericity showed that
assumption of sphericity was satisfied in the model examining FACT-G individually. When
FACT-G was examined independently in a repeated measures ANOVA, there was no significant
time by group interaction, (p = 0.244). See Figure 7. This corresponded to a small effect size
(Cohen’s d = 0.21).

Figure 10. Change in Functional Assessment of Cancer Therapy-General (FACT-G) Scores from
Baseline to Post-Treatment in SHUTi and Treatment as Usual (TAU) Groups (N=28; Outliers
Adjusted)
Functional Assessment of Cancer
Therapy-General (FACT-G) Score

80
78
76
74
72
70

TAU

68

SHUTi

66
64
62
60
Baseline

Post-Treatment

Discussion
The current study sought to address two complementary aims. The first aim was to
examine the feasibility and acceptability of implementing a low-intensity online CBT-I
intervention, SHUTi, to address insomnia among individuals who had been newly diagnosed
with cancer and were undergoing chemotherapy and/or radiation. Secondly, the study aimed to
evaluate the efficacy of SHUTi in improving sleep outcomes and secondarily, in decreasing
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psychiatric distress while increasing health-related quality of life. In pursuing these aims, the
study adds to previous scholarship that has proven CBT-I to be an efficacious, effective, and
durable treatment that can improve sleep and psychological well-being among cancer survivors.
The current study is also in line with an emergent, yet promising body of work that shows that
low-intensity versions of CBT-I such as self-directed treatment modalities, can achieve results
comparable to standard treatments without the high resource demands (Ritterband et al., 2012; J.
Savard et al., 2013). For instance, Savard and colleagues (2014) tested the efficacy of a lowintensity plus (optional) clinician support video-based CBT-I intervention and a face-to-face
CBT-I intervention in a sample of 242 breast cancer survivors. They found that the low-intensity
treatment resulted in small to large treatment effects on subjective sleep parameters that were
comparable, though not equivalent to the treatment effects observed in the standard treatment.
The remission rate in the low-intensity group (44.3%) was smaller than in the standard treatment
group (71.3%) but still statistically significantly greater than in the control group (25.7%) (J.
Savard et al., 2013). Yet, these studies have been plagued by limitations that threaten their
generalizability. Published studies have focused on samples that are primarily White, female,
and well educated (Berger, Kuhn, Farr, Von Essen, et al., 2009; Ritterband et al., 2012; J. Savard
et al., 2013). Disease sites in these studies have also been homogenous, with breast cancer being
overrepresented. Furthermore, previous studies have left the important question about the
possibility of addressing insomnia during the early and critical period immediately after cancer
diagnosis and during active treatment, largely unexamined. A literature search found only one
study that has tested CBT-I in women newly diagnosed with breast cancer who were undergoing
chemotherapy (Berger, Kuhn, Farr, Von Essen, et al., 2009).
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Based on the current state of the evidence, it was hypothesized that implementing
SHUTi, a low-intensity online CBT-I intervention, to treat insomnia among individuals who
were newly diagnosed with cancer and undergoing chemotherapy and/or radiation would be
feasible and would be found acceptable by participants. It was further hypothesized that SHUTi
would improve sleep as well as decrease anxiety and depression while enhancing health-related
quality of life. In all, these hypotheses were partially upheld. First, there was some support for
the feasibility and acceptability of addressing insomnia among survivors early in the cancer
trajectory. Second, there was preliminary evidence that a low-intensity intervention delivered
online with clinician support can improve sleep and decrease psychological distress.
Feasibility and Acceptability of SHUTi
Recruitment. A major success of the current study and a key piece of evidence in
support of feasibility is the successful recruitment of a diverse group of participants as they were
navigating a highly stressful part of their disease management. Overall, 70% of the patients who
were screened for the study were found to be eligible and of these patients, 100% initially agreed
to participate in the study and were enrolled. Among these participants, 91% (n=28) of the
participants completed all baseline assessments, constituting the final study sample that was
included in all analyses.
The participation rate in the current study is higher than rates previously observed in
similar studies. The only other published study that implemented CBT-I among individuals
newly diagnosed with cancer as they were undergoing chemotherapy reported a 70% enrollment
rate (Berger, Kuhn, Farr, Von Essen, et al., 2009) . Similarly, another intervention study
targeting fatigue in newly diagnosed patients undergoing chemotherapy reported a 71%
enrollment rate (Ream, Richardson, & Alexander-Dann, 2006). The high rate of participation
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observed in the present study is particularly noteworthy given concerns about overwhelming and
overburdening patients so early in their cancer diagnosis and treatment trajectory. In fact, this
was often a concern encountered by the doctoral student when discussing the study with certain
members of treatment teams. However, the rates of participation found in the current study as
well as in the aforementioned intervention studies implemented during active cancer treatment
have been higher than the rates (47-58%) found in other CBT-I studies that have addressed
insomnia post-cancer treatment (Epstein & Dirksen, 2007; Fiorentino et al., 2009; Ritterband et
al., 2012; J. Savard, S. Simard, H. Ivers, et al., 2005).
There are a number of features specific to the study design that likely contributed to the
participation rate. Patients may be more willing to participate in interventions that target side
effects and other psychological correlates of cancer during treatment because this phase is
especially stressful and thus they may have greater need for these services. There is support for
this hypothesis from a systematic review of studies on the unmet supportive care needs of people
with cancer that found that levels of unmet needs were highest during treatment. Yet patients
often fail to report their sleep difficulties to their oncologists (Engstrom, Strohl, Rose,
Lewandowski, & Stefanek, 1999). In the current study 60% of participants had not talked to
their oncologist about their insomnia. But that does not mean that patients are not seeking
services and/or help from other sources, whether that is from family members (Engstrom et al.,
1999) or from complementary and alternative medicine (CAM) modalities. Insomnia has been
identified as one of the most reasons that cancer survivors use CAM treatments (Mao, Palmer,
Healy, Desai, & Amsterdam, 2011). One study found that the greater the unmet need, the more
likely a cancer survivor was to use a CAM treatment (Mao et al., 2008). More specifically,
studies have reported that as many as 87 to 91% of individuals were using one or more
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complementary treatments (i.e., in addition to conventional treatment) during active treatment
(Yates et al., 2005). The addition of a CAM intervention was usually self-initiated rather than
being recommended by an oncologist. This suggests that newly diagnosed patients are especially
interested in adjunctive treatments during chemotherapy or radiation.
Nevertheless, recruiting newly diagnosed patients who have yet to begin treatment is
particularly challenging (Balogun et al., 2011). It is likely that there were qualities about the
current study that helped overcome some of these challenges. For one, the study employed a
low-intensity treatment modality, addressing newly diagnosed patients’ concerns about the
accessibility and convenience of non-pharmacological interventions for insomnia (Davidson,
Feldman-Stewart, Brennenstuhl, & Ram, 2007). It is noted that the two other studies of lowintensity CBT-I among individuals with cancer reported participation rates ranging from 50-55%
(Ritterband et al., 2012; J. Savard, Villa, et al., 2011). Thus it is likely that it was the timing of
the current study during treatment when need is high, as well as its low-intensity modality that
helped boost the participation rate. The current study was also flexible. Participants were
informed that the doctoral student could meet with them during their medical appointments,
rather than requiring additional meetings. Participants who experienced delays in their treatment
were also able to resume participation after their delays. Cancer survivors have cited flexibility
as being key to participation in insomnia interventions (Davidson et al., 2007).
Sample diversity. In addition to being feasible in terms of the availability and
willingness of the study population, the racial and ethnic diversity of the current study supports
the feasibility of studying the efficacy of low-intensity CBT-I among minority cancer survivors.
Racial and ethnic minorities made up approximately one-third of the current study sample (30%
African American). This proportion is greater than has been included in past studies of CBT-I in
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cancer, where racial and ethnic minorities, when included, have made up 4 to 18% of the studied
samples (Berger, Kuhn, Farr, Von Essen, et al., 2009; Epstein & Dirksen, 2007; Fiorentino et al.,
2009; Ritterband et al., 2012). The importance and challenge of recruiting minority participants
to intervention studies is well established (Areán, Alvidrez, Nery, Estes, & Linkins, 2003; D. R.
Brown, Fouad, Basen-Engquist, & Tortolero-Luna, 2000; Swanson & Ward, 1995; Yancey,
Ortega, & Kumanyika, 2006). One factor that likely contributed to the success of recruiting
African Americans in the current study is the race of the doctoral student. The doctoral student
is Black and having her as the face of the study likely facilitated the participation of African
American patients that were approached. There is evidence that suggests that race concordance
between participants and interviewers corresponds to higher participant cooperation rates,
especially among Black participants (Moorman, Newman, Millikan, Tse, & Sandler, 1999).
However, race concordance is not sufficient for successful minority recruitment (Areán et
al., 2003). It is likely that the other features of the study, namely the availability of a tablet, the
flexibility, and convenience of the study also contributed to the sample diversity. As previously
stated, all African American participants in the SHUTi condition chose to meet with the doctoral
student and use the tablet to complete cores during their appointments. The availability of the
study tablet likely mitigated any barriers that may have been related to Internet access. In fact,
one African American participant explained that the Internet access in her home became
unreliable during the study period. Additionally, the flexibility and convenience of the study
(i.e., no additional meetings) as previously described, likely contributed to a higher participation
rate. In sum, providing participants with a tablet for use during their appointments and allowing
them flexibility likely contributed to an overall higher rate of participation in the current study,
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however, these factors (i.e., economic barriers, treatment schedule) have been shown to be more
likely to influence minority participation in cancer studies (Giuliano et al., 2000).
Doctoral student support. When it comes to the study feasibility, the support of the
doctoral student cannot be overstated. As one participant described, “I don’t know how
acceptable or effective the program would have been without the counselor.” Of note, this is not
the first study to employ clinician support as an adjunct to a self-help CBT-I intervention in
individuals with cancer (J. Savard et al., 2013). However, in the previous study, very few of the
participants accessed clinician support. Thus this is one of the first self-help CBT-I studies in
individuals with cancer to report on how participants used clinician support. One of the most
telling findings from the current student is that among SHUTi completers, when compared to
participants who initially chose to complete SHUTi on their own (n=5), participants who initially
accepted the doctoral student’s support (n=6) completed the program faster (10 weeks vs. 16
weeks). Moreover, a significant minority of participants randomized to SHUTi (27%; n=4)
likely only completed SHUTi after much delay because of having the doctoral student’s support
to assist in completing each core. This finding suggests that having the doctoral student’s
support had a considerable impact on the completion rate as well as the time to complete.
Meeting with patients at their weekly or biweekly medical appointments made it much less likely
that patients would forget to complete a core, thereby cutting down on delays. It may also have
served to maintain participants’ commitment to the program as meeting with the doctoral student
was a frequent reminder that the study was ongoing.
Also worth discussing is how participants who initially accepted the doctoral support
differed from the rest of the SHUTi group. These participants were more likely to be African
American and to be from a lower socioeconomic class. Recruitment and retention of African
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Americans and individuals from lower socioeconomic status is critical to ensuring the
generalizability of observed treatment effects. Past studies have found that participation and
retention rates tend to be lower among Black participants and those from lower socioeconomic
classes (Murthy, Krumholz, & Gross, 2004). Yet the current study shows that when provided
with the option of additional support, these participants may be more likely to access this support
and with this additional support, they can demonstrate similar if not better participation and
retention rates than other participants. Having the support of the doctoral student, who is Black,
may have been especially effective at facilitating minority participation because it enhanced the
qualities of research studies most likely to encourage participation among black and poor
research participants—convenience of program location and timing, as well as the enthusiasm
and trustworthiness of study staff (Gross, Julion, & Fogg, 2001).
Acceptability. An important indicator of a study’s feasibility is its reception among its
intended target population. Findings from the current study suggest that in general, participants
found SHUTi to be an acceptable intervention for addressing their sleep difficulties. Put another
way, 79% found the program to be mostly or very acceptable for themselves and 64% believed
that it would be mostly or very acceptable for others like them. These findings suggest that
despite some participants concerns about having a sleep intervention while they were in the early
stages of cancer treatment, most participants had a positive response and felt the program would
be helpful to others like themselves.
Other findings regarding the program’s utility and effectiveness can be compared to
findings from the only other study to examine the acceptability of SHUTi in a sample of
individuals with insomnia (Thorndike et al., 2008). In the previous study, 100% of participants
reported that SHUTi was mostly or very easy and convenient to use. Nearly all participants
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(95%) indicated that the program was mostly or very understandable. The current study found
somewhat similar results. Most participants (79%) found SHUTi easy and convenient to use.
All participants indicated that the program was mostly or very easy to understand. On other
hand, there were some discrepancies between the past and current findings. Whereas Thorndike
and colleagues (2008) reported that 90% of their sample found SHUTi to be consistent with what
they heard from their doctors, only 46% of participants in the current study found the program to
be consistent. Similarly, 81% of the sample from the previous study rated the program as being
mostly or very effective as a long-term cure, while 62% stated that they were mostly or very able
to follow through with treatment recommendations. In contrast, only 36% of participants in the
current study felt the program would be effective and only 36% reported being adherent. The
discrepancy in how consistent SHUTi is with providers’ recommendations may be partly
explained by the inconsistency between oncologists’ encouragement that patients rest during
treatment and instructions from stimulus control to only go to bed when sleepy. Such
inconsistencies may also help explain why so few patients felt they were able to adhere to the
program’s recommendation. One participant’s comment that it did not seem like SHUTi was
especially relevant for individuals who are medically compromised, lends further support to this
argument. Participants may have been less adherent because they felt less capable of doing so
because of physical limitations. Lastly participants may have been less confident in SHUTi as an
effective long-term cure also because they were sick while undergoing the program. Most
participants (86%) reported that their cancer diagnosis had adversely affected their sleep, thus
they may have felt that only the successful treatment of their disease would effectively address
their sleep problems. It is important to note that even though less than one-half of participants
reported being adherent to the program and only a little over one-third indicated that the program
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would be an effective long-term cure, SHUTi was proven to be efficacious at improving sleep
and psychological distress among participants.
SHUTi Treatment Effects on Self-Reported Sleep
The baseline sleep parameters in the current study were somewhat comparable to those
reported in a recent meta-analysis of 8 randomized controlled trials of CBT-I efficacy in cancer
survivors (Johnson et al., 2016). The mean SE for participants randomized to SHUTi in the
current study was 72.8% compared to 74.9% in previous studies. The mean WASO in the
current study was 51.8 minutes compared to 61.5 minutes and the mean SOL in the current study
was 50.3 minutes compared to 41.3 minutes in previous studies.
It is noteworthy that there was a small difference in mean ISI scores, 14.0 in the current
study compared to 17.1 in previous studies. Given the similarities in other sleep parameters, this
difference suggests that even though participants in the current study were reporting sleep
parameters consistent with insomnia, they were not as distressed about these symptoms as has
been observed in previous studies. This difference may be due to the fact that whereas most of
the participants in previous studies have been months and years past their cancer diagnosis and
treatment (Epstein & Dirksen, 2007; Ritterband et al., 2012), participants in the current study
were on average within the first two months of their cancer diagnosis. One theoretical
framework that has been advanced to understand how the co-occurrence of psychiatric and
physical conditions influences the treatment of psychiatric symptoms is the “crowd-out effect”
(Lê Cook, McGuire, Alegría, & Normand, 2011). This framework postulates that when patients
experience both physical and psychiatric conditions concurrently, they may be more likely to
focus on the physical condition as being more critical. This tendency to prioritize physical
conditions over psychiatric symptoms may be even more pronounced in this sample given the
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proximity of the cancer diagnosis. It is important to note that even though participants in the
current study reported less insomnia-related distress than has been found in previous studies,
their level of distress is nevertheless above the cut-off score (10) determined to differentiate
between non-clinical and clinically significant sleep difficulties (Morin, Belleville, Bélanger, &
Ivers, 2011).
Findings from the current study showed that when compared to participants who received
TAU, participants who completed at least 30% of SHUTi (79% had 100% completion rate)
showed significant improvement on a global measure of insomnia and on several specific sleep
parameters. On the ISI, considered by many to be the most reliable single measure of sleep
(Smith & Wegener, 2003) , there was a 55% decrease in the mean ISI score from 14.0 to 6.3 in
the SHUTi group, compared to a 5% decrease from 13.4 to 12.8 in the TAU group. Research
suggests that an ISI reduction of > 7 indicates moderate improvement while a reduction of > 8
indicates marked improvement (Morin et al., 2011). There was complete remission in the
SHUTi group, as the mean ISI score was reduced from the clinical range to the non-clinical
range while the mean for the TAU group remained in the clinical range. With regard to WASO,
there was a similar 55% decrease in the SHUTi group (51.8 to 23.3 minutes) compared to a 7%
increase in the TAU group. There was a marginally significant treatment effect found for SE.
There was a 12-percentage point increase in the SHUTi group compared to a 0.4-percentage
increase in the TAU group. The mean SE for the SHUTi group achieved the normal range cutoff of 85%.
Although there were larger improvements in SOL and TST in the SHUTi group than in
the TAU group, there were no significant time by group interactions. There was a 28% decrease
in the mean SOL in the SHUTi group (50.3 to 36 minutes) compared to a 16% decrease in the
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TAU group (77.5 to 65.1 minutes). Nevertheless, the mean SOL for both the SHUTi and the
TAU groups were above the generally accepted clinical cut-off of 30 minutes. The lack of a
significant time by group interaction for SOL suggests that the improvement in SE is due to the
decrease in WASO rather than the decrease in SOL. The mean TST for the SHUTi group
increased by 63 minutes compared to an 18-point increase in the TAU group. Thus the lack of
significant findings for these variables may have been due to limited power due to the small
sample size even though this sample size is consistent with previous power analysis calculations
(Ritterband et al., 2012).
To contextualize the current findings in the literature, there are a number of different
comparisons. First, these findings can be compared to the broader literature on the effects of
CBT-I among cancer survivors as reported in a recent meta-analysis (Johnson et al., 2016).
However, this comparison is limited by the fact that all of these studies have been with cancer
survivors rather than with individuals with new diagnoses who are undergoing treatment. To
address this shortcoming, the present findings can be compared to the only other published study
of CBT-I on patients with new diagnoses undergoing chemotherapy (Berger, Kuhn, Farr, Von
Essen, et al., 2009). While this is not a perfect comparison, the study’s use of a hybrid face-toface and self-help model is similar to the current study’s use of clinician support as an adjunct to
online treatment. Third, the current findings can also be compared to a previous test of SHUTi
in a group of cancer survivors (Ritterband et al., 2012).
Although overall similar, the effect sizes from the current study are smaller than have
been reported in the larger literature on CBT-I in cancer (Johnson et al., 2016) and more
comparable to findings reported in the previous trial of SHUT (Ritterband et al., 2012). For
example, there were large effect sizes reported for ISI (1.74), WASO (0.98), and SE (0.99) in the
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meta-analysis compared to moderate effect sizes for ISI (0.60) and WASO (0.49) and a small
effect size for SE in the current study. In the previous SHUTi trial, the effect size for ISI was
large (1.85) while the effect size for SE (0.72) was medium to large and was small for WASO
(0.22). This is not unexpected, as all but one of the studies included in the meta-analysis are of
standard, face-to-face CBT-I while SHUTi is a low-intensity version. The smaller effect sizes
observed in the current study for ISI and SE when compared to the previous SHUTi trial may be
partially explained by the fact that the current sample was more medically compromised. Posttreatment data for the current study was collected on average, 4 months after cancer diagnosis. A
longitudinal study of the course of insomnia in cancer showed that among individuals with
insomnia syndrome at diagnosis, there is a 92% persistence rate at 6 months after diagnosis
compared to only a 38% 18 months after diagnosis (J. Savard, Ivers, et al., 2011). Previous
intervention trials have also found variations in treatment effects by time since diagnosis and
treatment status at time of intervention. Specifically, one study found that whereas an exercise
intervention significantly improved sleep quality among participants who had indolent cancer,
there were no treatment effects in participants with active disease (Courneya et al., 2012). While
not focused on sleep-related outcomes, a meta-analysis of exercise interventions among
predominantly breast cancer samples found that there were larger treatment effects on patientreported outcomes during the post-oncology treatment phase than during treatment (Schmitz et
al., 2005; Speck, Courneya, Mâsse, Duval, & Schmitz, 2010). Thus the current study provides
support for the efficacy of CBT-I during the early stages of cancer diagnosis and treatment, while
also demonstrating that given the acuity of distress (Carlson et al., 2004; Hanson Frost et al.,
2000) during this period, treatment effects may be blunted.
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Notably, the one exception was WASO, where the current study found a medium effect
size whereas the previous SHUTi trial found a small effect size (Ritterband et al., 2012). In fact,
there was no significant group by time effect in the previous trial. In the current study, this was
the only sleep parameter wherein there was a slight worsening in the TAU group at posttreatment. The current findings also differ from results described in the only other study of
CBT-I during active treatment (Berger, Kuhn, Farr, Von Essen, et al., 2009). In the previous
study, the authors failed to find a significant group by time effect as found in the current study.
However, they did find that only participants in the treatment group and not in the control group
experienced a significant decrease in WASO. The current findings indicate that WASO may be a
particularly relevant indicator of poor sleep during the early stages of cancer diagnosis and
treatment. This assertion is supported by similar findings that without intervention, WASO
increased during chemotherapy and only decreased after chemotherapy. Thus CBT-I is more
likely to have an effect on WASO during this phase of the cancer trajectory. It is generally
argued that differences in how insomnia symptoms are manifested (difficulties in initiating vs.
maintaining sleep) are negligible due to the instability of these symptom differences (Hohagen et
al., 1994) and consequently these differences are not given much consideration when it comes to
designing interventions for treatment trials. Yet studies have consistently showed that there are
variations in how CBT-I affects different sleep parameters. Past research indicates that while
stimulus control and sleep restriction are the most effective components of CBT-I (Kyle et al.,
2015; Morgenthaler et al., 2006; Smith et al., 2002), cognitive restructuring (i.e., changing
unhelpful thoughts about sleep) and cognitive control (i.e., addressing thoughts, worries early in
the evening) are especially helpful for consolidating sleep (Edinger et al., 2001b). There is also
evidence that cognitive arousal is associated with more nighttime awakenings and greater sleep
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fragmentation (Rasskazova, Zavalko, Tkhostov, & Dorohov, 2014). Thus the significance of
WASO during cancer treatment and the larger effect of SHUTi on WASO in the current study in
comparison to the previous SHUTi trial implicates the particular relevance of thoughts in this
sample. There is evidence that supports the notion that cancer-related worry thoughts are
especially salient soon after diagnosis and during treatment (Antoni et al., 2009).
In contrast, there were no significant treatment effects for SOL and TST. The findings
regarding TST are in line with findings from the previous SHUTi trial (Ritterband et al., 2012).
They are also similar to previous trials that have failed to find treatment effects to TST despite
improvements in other sleep parameters (Espie et al., 2008; J. Savard et al., 2013). A possible
explanation is that CBT-I initially aims to improve sleep efficiency by narrowing participants
sleep window to consolidate sleep. Expanding the sleep window, which is more likely to have
an impact on TST occurs later in treatment. Thus the current intervention may not have allowed
a long enough study period to detect changes in TST (Espie et al., 2008). Unlike TST, SOL has
typically been shown to be responsive to CBT-I (Ritterband et al., 2012; J. Savard et al., 2013).
The null results in the current study along with the fact SOL was the only sleep parameter that
remained in the clinical range in both the SHUTi and TAU group, may have to do with the
prevalence of cancer-related physical symptoms. Physical symptoms including pain, which are a
major precipitating factor for insomnia in cancer (Theobald, 2004), have been shown to
specifically contribute to difficulty initiating sleep (Mercadante, Girelli, & Casuccio, 2004).
Given that pain and other physical symptoms are more prevalent during treatment than after
treatment (Van den Beuken-van Everdingen et al., 2007), it may explain why this sleep
parameter was refractory to treatment in the current study. Furthermore, there is evidence that
only face-to-face behavioral treatments for insomnia, as opposed to those delivered over the
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Internet or over the telephone, improve sleep in patients with cancer or non-cancer pain (Tang et
al., 2015).
SHUTi Treatment Effects on Depression and Anxiety Symptoms
Findings showed that SHUTi was associated with a significant and medium sized
improvement in depressive symptoms. At baseline, participants in the SHUTi and TAU groups
reported moderate depressive symptoms. Post-treatment, the SHUTi group exhibited a 4-point
decrease in PHQ-9 scores, signifying a decrease in depressive symptoms from the moderate to
mild range. In contrast, PHQ-9 scores in the TAU group were largely unchanged (-0.7
decrease), the mean score for the group is at the upper limit of the mild range and close to the
recommended cut-off score (10) suggested for clinical attention (Morin et al., 2011). Posttreatment, only two participants in the SHUTi group (14.3%) reported a score that was above the
clinical cut-off, compared to 4 or 28.6% in the TAU group. Previous trials of CBT-I in cancer
have reported mixed findings with regard to treatment effects for depression. Some studies have
failed to find a treatment effect (Matthews et al., 2012; Ritterband et al., 2012). Among the
studies that have found a treatment effect for depression, the effect size has been in the medium
range (Espie et al., 2007; J. Savard et al., 2013), while the effect size in low-intensity modalities
have been more similar to the current results and have been in the small range (J. Savard et al.,
2013). Ritterband et al (2012) found that while SHUTi did not have a significant effect on
depressive symptoms, there was a medium treatment effect size.
There was no treatment effect for anxiety. There was a significant time effect that was
similar across the two groups, such that there was a 2-point decrease in the mean GAD-7 score
for the SHUTi group compared to a 3-point decrease in the TAU group. At post-treatment, both
groups were reporting mild anxiety symptoms. This type of discrepancy in the treatment effects
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of CBT-I on psychological symptoms is uncommon in the literature. For the most part, studies
have found that the presence or absence of treatment effects has been similar for depression and
anxiety. For example, Espie and colleagues (2007) found that group CBT-I was associated with
a medium sized treatment effect for depression and anxiety, while Ritterband et al. (2014) found
that SHUTi did not significantly improve depressive or anxiety symptoms. There is only one
other study that found that whereas face-to-face CBT-I had a significant effect on depression and
anxiety, video-based CBT-I significantly improved depression but not anxiety (J. Savard et al.,
2013). An argument could be made that this difference is related to the intensity of the
intervention, such that standard CBT-I may be more effective in addressing anxiety than
depression. However, the fact that several standard CBT-I trials have failed to find treatment
effects for anxiety and findings from the previous SHUTi trial also showed that there was no
significant treatment effect on anxiety suggests that there may be another explanation. Instead, it
seems more plausible that there may be a difference in the nature of depression versus anxiety
that makes the former more responsive to CBT-I. In the current study, anxiety scores decreased
for all participants, while depression only decreased in the SHUTi group. This idea is
substantiated by findings from a recent meta-analysis of non-pharmacological sleep treatments in
chronic pain that while treatment conferred benefits for depression post-treatment and at followup, there was no treatment benefit for anxiety (Tang et al., 2015). Similarly, another metaanalysis found a significant medium effect size for CBT-I on depression while the effect for
anxiety outcomes was small and non-significant, suggesting that CBT-I is more effective for
depression than for anxiety (Belleville, Cousineau, Levrier, & St-Pierre-Delorme, 2011;
Sánchez-Ortuño & Edinger, 2012). Given the timing of the current study and its proximity to
participants’ diagnosis and treatment, patients’ anxiety was likely more related to cancer, and
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thus more responsive to the natural course of decreasing worry as patients adjust to their
diagnoses and treatment.
SHUTi Treatment Effects on Health-related Quality of Life
At baseline, the mean FACT-G total score was 72.2. This score is lower than has been
reported in normative data for a heterogeneous oncology sample (80.9) (Brucker, Yost, Cashy,
Webster, & Cella, 2005) and in a previous study of CBT-I in cancer (80.1) (Espie et al., 2008),
indicating worse health-related quality of life for the current sample. There were substantial
differences between the mean component scores for the current study and normative data
reported for individuals with cancer, such that for emotional and functioning well-being, the
differences were clinically meaningful. These differences are consistent with the current sample
being sicker.
There was no treatment effect observed for overall health-related quality of life or its
components. There was no significant time effect, unlike in the case of sleep-related outcomes
and psychological symptoms, suggesting that FACT-G total scores did not change from baseline
to post-treatment. There was a 5-point increase in the mean total score for the entire sample,
while there was a 9-point increase in the SHUTi group compared to a 1-point increase in the
TAU group. It is likely that this difference may not have reached statistical significance due to
the small sample size, especially since the increase in the SHUTi group was clinically
meaningful. However, it is also possible that there is no treatment effect. A previous study of
face-to-face CBT-I found medium to large effects for health-related quality of life. On the other
hand, the previous SHUTi trial failed to find treatment effects for quality of life, but a videobased self-directed trial found a small positive effect. The current sample was sicker than has
been studied previously and on the whole, reported worsening physical well-being at post-

85

treatment. It is possible that improvements in certain components of the FACT-G (i.e.,
emotional well-being) were canceled out by worsening physical well-being. Despite a slight and
clinically non-significant increase in the mean physical well-being score for the SHUTi group
(+0.7), the mean scores for both groups were substantially lower than the mean reported for a
normative sample, 18.5 in SHUTi and 18.9 in TAU compared to 22.7 and for a sample with
cancer, 21.3. The mean total FACT-G scores also remained lower than reported in normative
data. Thus even at post-treatment, the sample continued to feel burdened by their disease, which
makes sense since many were still engaged in active treatment.
Limitations
The current findings must be interpreted in the context of several limitations. First, the
sample size was small and may have limited the ability to detect some treatment effects. This
was particularly relevant when it came to outcomes like the TST and health-related quality of life
wherein the mean scores for the SHUTi group differed considerably from the TAU group, yet
there was no significant time by group interaction found. The current sample size was based on
power calculations reported in previous studies. Moreover, the sample size in the current study
is comparable to sample sizes that have been used in similar studies in the past (Fiorentino et al.,
2009; Ritterband et al., 2012). However, the consistent time effects observed across most of the
outcomes in the current study is consistent with past evidence that during this early phase of the
cancer trajectory, there are substantial changes in patients’ sleep and psychological well-being
(Bárez, Blasco, Fernández-Castro, & Viladrich, 2009; J. Savard, Ivers, et al., 2011; Schroevers,
Ranchor, & Sanderman, 2006). Thus, a larger sample size may be required to detect time by
group interactions. However, this also makes the observed treatment effects that much more
credible.
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Another limitation of the current study is the use of only self-reported sleep parameters.
The observed effects on sleep may have been even more convincing if they had been further
substantiated by treatment effects on objective sleep measures. The inclusion of subjective and
objective sleep measures is especially important given past mixed findings about differences in
CBT-I effects by type of sleep measure (Lund, Rybarczyk, Perrin, Leszczyszyn, & Stepanski,
2013). However, this was a small pilot study and adding objective sleep measures was not
feasible. Additionally, there are other studies in this area that have only used self-reported sleep
measures (Matthews et al., 2014; Ritterband et al., 2012).
A third study limitation is the lack of a follow-up data to assess the durability of
treatment effects. Studies that have evaluated study outcomes at follow-up have found that there
are important changes in outcomes that contribute important information about treatment effects.
Whereas some studies have found that some treatment effects diminish over time (Taylor et al.,
2015), others have found that for some outcomes, the treatment effects are actually enhanced at
follow-up (Espie et al., 2008; J. Savard, S. Simard, H. Ivers, et al., 2005). Thus follow-up data in
the current study may have helped shed light on whether treatment effects would emerge or
increase at follow-up when participants are likely done with their cancer treatment and thus may
be more able to adhere to SHUTi recommendations. Yet this is not the first study in this area to
exclude follow-up data (Epstein & Dirksen, 2007; Ritterband et al., 2012; J. Savard et al., 2013).
On a related note, the poor health status of some of the study participants likely
contributed to the study delays and may have dampened some treatment effects. The study
aimed to evaluate SHUTi during active cancer treatment, so it was expected that participants
would be sick. However, 18% of the current sample had stage IV malignancies. These patients
were not diagnosed with widely metastatic disease and thus were planned to undergo curative
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treatment, making them eligible for the current study. This is not the first study of its kind to
include participants with stage IV disease (Ritterband et al., 2012). But given that this study was
during treatment, it is likely that stage IV disease was more impactful. The inclusion of these
patients contributes further to the generalizability of the current findings.
A final limitation is that the doctoral student was responsible for randomization, data
collection and implementing the intervention. Thus, blinding the experimenter was impossible,
which may have contributed to demand effects (Orne, 1962). However, this threat to validity is
mitigated by the fact that the intervention was a standardized program delivered online. Even
though the doctoral student provided some support to all but one of the participants in the
treatment condition, the core intervention was standardized.
Strengths
This study has several strengths. A major strength of the current study is the diversity of
the sample, which enhances the external validity of findings. In recruiting a study sample that is
diverse in race, socioeconomic status and type of malignancy, the current study addresses a
significant gap in the literature. Previous samples have been primarily White, well-educated
women with breast cancer. For example, this is one of the first studies to include patients with
head and neck cancer. The current study suggests that online CBT-I can also be effective in
other types of cancers as well as among Black individuals and those from lower socioeconomic
strata.
Another strength of the present study is the inclusion of clinician support. There is
previous support that low-intensity CBT-I interventions can be enhanced with the addition of
clinician support (Ho et al., 2014; Jernelöv et al., 2012). However, previous trials that have
included clinician support have found that participants have not taken advantage of this option (J.
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Savard, Villa, et al., 2011). Evaluating clinician support was more feasible in the current study
because the doctoral student was able to monitor participants’ progress through SHUTi and there
were multiple opportunities to offer support during participants’ medical appointments. In the
current study Black participants and those from lower socioeconomic status appeared to be more
likely to initially accept the doctoral student’s support. While it was not possible to test these
hypotheses, it does suggest research questions for future inquiry. Also, flexibly offering
clinician support rather than using randomization or having participants select an option at the
beginning of treatment, more closely approximates how treatment would naturally unfold in a
non-research clinical context.
Implications
Findings from the current study have implications for scholarship and clinical practice.
Related to one of its primary aims, the first implication from the current study is about
feasibility. Overall, the current findings support the feasibility of implementing a low-intensity
CBT-I intervention to improve sleep among individuals newly diagnosed with cancer and
undergoing active treatment. Future research should consider the following caveats. First, given
that participants tend to be sicker during treatment, future studies should build in additional time
to account for illness-related delays. There should also be flexibility to allow participants to
continue the study if there are delays and building research activities around medical
appointments substantially decreases the burden on participants, thus encouraging participation.
On a related note, having a study tablet that allows participants to complete study activities
during their medical appointments also facilitates participation. This also serves to increase
participation by minority and low-income individuals. To that end, the current study adds to
accumulated evidence that when minority and low income individuals are recruited and the
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barriers to their participation minimized, they are just as likely if not more likely than other
groups to participate in research studies (Wendler et al., 2005).
The treatment effects on self-reported sleep parameters and psychological functioning
have significance for addressing insomnia during cancer treatment. Namely, low-intensity CBTI can have a meaningful impact on sleep and depression even during this particularly stressful
phase of the cancer care trajectory. Wake time after sleep onset may be especially responsive to
treatment during this time, perhaps because intrusive thoughts are at a peak during this period.
Yet, anxiety is less responsive to CBT-I likely because patients’ anxiety is more closely tied to
their disease. Health-related quality of life may be similarly unaffected by low-intensity CB-I.
These findings suggest that during cancer treatment, other outcomes may be more suitable for
capturing the secondary effects of CBT-I. One possibility is fatigue. Fatigue has been examined
as a secondary outcome in multiple CBT-I trials among individuals with cancer (Espie et al.,
2008; Ritterband et al., 2012; J. Savard, S. Simard, H. Ivers, et al., 2005). Fatigue was also
included in the previous evaluation of CBT-I during cancer treatment (Berger, Kuhn, Farr, Von
Essen, et al., 2009). The current findings also highlight the importance of assessing multiple
sleep parameters and not relying solely on global measures of insomnia. During the period
immediately after diagnosis when they are about to embark on treatment, patients may
underreport the distress related to their sleep difficulties because they may be more inclined to
attend to their physical illness.
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Study eligibility questionnaire
Clinical Interview
Sleep diary
Insomnia Severity Index (ISI)
Patient Health Questionnaire-9 (PHQ-9)
Generalized Anxiety Disorder-7 (GAD-7)
Functional Assessment of Cancer Therapy-General scale (FACT-G)
Treatment preference questionnaire
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Study Eligibility Questionnaire
1. Have you been diagnosed with non-metastatic cancer?
2. Will you undergo chemotherapy or radiation treatment?
3. Is this the first time you will undergo chemotherapy or radiation treatment?
4. Do you experience at least three episodes of disturbed sleep per week AND daytime
consequences such as fatigue, irritability, or difficulty concentrating that has lasted for at
least one month?
a. An episode of insomnia is defined as:
i. An inability to fall asleep within 30 minutes
AND/OR
ii. Awakening during the night (after falling asleep) for a total of 60 minutes
or more
AND/OR
iii. Achieving less than 6.5 hours of sleep per night
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Participant information/Demographic questionnaire
1. When were you diagnosed with cancer?
2. When do you begin treatment?
3. For how long have you experienced the following symptoms? _____years _____months
a) At least three episodes of disturbed sleep per week
AND
b) Daytime consequences such as fatigue, irritability, or difficulty concentrating?
4. When did you first notice you were having problems with your sleep?
___Before cancer diagnosis
___After cancer diagnosis
5. Have you ever told your oncologist about these sleep problems?
___Yes ___No
6. Do you believe that your cancer diagnosis and/or treatment caused your sleep
problems?
___Yes ___No
7. Do you believe that your cancer diagnosis and/or treatment has affected your sleep?
___Yes ___No
8. Are you taking any sleep aids, either prescribed or over the counter?
___Yes ___No
9. Please tell me your age: _____
10. Gender: ____Male

____Female

11. Marital status: ____Married

____Single

____Divorced/Separated/Widowed

12. Race/ethnicity: ___Hispanic/Latino
_____African American/Black
_____American Indian/Alaskan
_____Asian

____not Hispanic/Latino
____Native Hawaiian/Other Pacific Islander
____White
____Two or more races

13. Education:
___Some high school
___High school
___Some college

____College
____Graduate school

14. Please indicate your household income
___< $10,000
___$10-29,999

106

___$30-49,999
___$50-74,999
___$75-99,999
___$100,000+
15. What is your employment status?
___Full-time
___Part-time
___Retired
___Disabled
___Other
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In order to better understand your sleep problem and monitor your progress
while using SHUTi, it is important to collect some information on your sleep
pattern.
General Instructions
•

What is a Sleep Diary? A sleep diary is designed to gather
information about your daily sleep pattern.

•

How often and when do I fill out the sleep diary? It is necessary
for you to complete your sleep diary every day. If possible, the
sleep diary should be completed within one hour of getting out of
bed in the morning.

•

What should I do if I miss a day on this paper version of the
diary? If you forget to fill in the diary or are unable to finish it,
leave the diary blank for that day. If you complete this paper diary
but do not enter it into SHUTi that day, you can enter up to 3 days
worth of diaries at one time (today, yesterday, and the day before).

•

What if something unusual affects my sleep or how I feel in the
daytime? If your sleep or daytime functioning is affected by some
unusual event (such as an illness, or an emergency) you may make
brief notes on your diary.

•

What do the words “bed” and “day” mean on the diary? This
diary can be used for people who are awake or asleep at unusual
times. In the sleep diary, the word “day” is the time when you
choose or are required to be awake. The term “bed” means the
place where you usually sleep.

•

Will answering these questions about my sleep keep me awake?
This is not usually a problem. You should not worry about giving
exact times, and you should not watch the clock. Just give your best
estimate.
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Sleep Diary Instructions
Use the guide below to clarify what is being asked for each item of the Sleep Diary.
Question 1:

What time did you get into bed?
Write the time that you got into bed. This may not be the time you began “trying” to
fall asleep.
Question 2:

What time did you try to go to sleep?
Record the time that you began “trying” to fall asleep. This is the time you go to bed
with the intention of falling asleep. It should not include time in bed when you did
not intend to fall asleep (that is included in Question 1). If you go to bed at 10:15
PM, but do not turn the lights off with the intention of going to sleep until 11:30
PM, you should enter 10:15 PM inQuestion 1 and 11:30 PM for this question. If
you go to bed at 10:15 PM with the intention of going to sleep right away, but then
do not fall asleepuntil 11:30 PM, you should write down 10:15 PM for both
questions. Thenext question will capture how long it took to fall asleep.
Question 3:

How long did it take you to fall asleep?
Beginning at the time you wrote in question 2, how long did it take you to fall asleep.
Enter your answer in hours and minutes. Provide your best estimate of how long it
took you to fall asleep once you got into bed and turned off the lights with the
intention of going to sleep. If you go to bed at 10:15 PM with the intention of going to
sleep, but then do not fall asleep until 11:30 PM, you should write down 1 hour 15
minutes (75 minutes total) in this space.
Question 4:

How many times did you wake up, not counting your final awakening? How
many times did you wake up between the time you first fell asleep and your final
awakening? This is the number of times you remember waking up during the
night.
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In total, how long did these awakenings last?
What was the total time you were awake between the time you first fell asleep and
your final awakening. Enter your answer in hours and minutes. For example, if you
woke 3 times for 20 minutes, 35 minutes, and 15 minutes, add them all up
(20+35+15= 70 min or 1 hr and 10 min). Estimate to the best of your knowledge how
many minutes you spent awake for all awakenings combined. This should not
include your very last awakening in the morning, as this will be logged in the next
question (Question 6).
Question 6:

What time was your final awakening?
Record the last time you woke up in the morning. This is the very last time you
woke up in the morning. If you woke up at 4:00 AM and never wentback to sleep,
this is the time to write. However, if you woke up at 4:00AM, but went back to
sleep for a brief period of time (for example, from6:00 AM to 6:35 AM; this
information would then be included in Questions4 and 5), then your last
awakening would be 6:35 AM.
Question 7:

What time did you get out of bed for the day?
What time did you get out of bed with no further attempt at sleeping? This may be
different from your final awakening time (e.g., you may have woken up at 6:35 AM
but did not get out of bed to start your day until 8:20 AM).
Question 8:

How would you rate the quality of your sleep?
“Sleep Quality” is your sense of whether your sleep was good or poor. Please use the
following 5-point scale to indicate how you felt when yougot up in the morning:
(1=Very Poor, 2=Poor, 3=Fair, 4=Good, 5=Very Good)
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Question 9:

In total, how long did you nap or doze?
Estimate the total amount of time you spent napping or dozing, in hours and
minutes. For instance, if you napped twice, once for 30 minutes and once for 60
minutes, and dozed for 10 minutes, you would answer 1 hour 40 min.
This should include all naps even if they were not intentional. For instance, if you
dozed off in front of the TV for 30 minutes, this should be included. If you did not
nap or doze, select 0 (zero).
Question 10a:

How many drinks containing alcohol did you have?
Enter the number of alcoholic drinks you had where 1 drink is defined as one 12 oz
beer (can), 5 oz wine, or 1.5 oz liquor (one shot).
Question 10b:

What time was your last drink?
If you had an alcoholic drink yesterday, enter the time of day in hours and minutes of
your last drink. If you did not have a drink, write “N/A” (not applicable).
Question 11:

Did you take any over-the-counter or prescription medication(s) to help
you sleep? If so, list medication(s), dose, and time taken:
List the medication name, how much and when you took EACH different medication
you took tonight to help you sleep. Include medication available over the counter,
prescription medications, and herbals (example: "Zolpidem 10 mg 10 pm"). If every
night is the same, write “same” after the first day.
Comments:
If you have anything that you would like to say that is relevant to your sleep feel free
to write it here.
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